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Anorexia nervosa is considered to be a difficult disorder to treat in adults (Fairburn, 2005). 
The current study aimed to explore the effectiveness of metacognitive therapy modified for 
anorexia nervosa as a new intervention approach for individuals struggling with this disorder. 
In this sequential exploratory study; twelve patients diagnosed with either typical or atypical 
anorexia nervosa were recruited from the South Island Eating Disorders Clinic to receive 
adapted metacognitive therapy for anorexia nervosa. The number of therapy sessions that 
patients received in this study ranged from 11-42 sessions. Data analysis was conducted at 
the group level and individual level.  The results of the study found that patients showed 
some decreases in their eating disorder symptoms and some showed an increase in BMI 
following modified MCT. Group data showed that there was also an observed decrease in the 
groups maladaptive metacognitions, with individual analysis showing promising findings of 
clinically significant changes of reductions in patients positive beliefs about worry after 
receiving MCT.  However, individual analysis of clinically significant changes revealed that 
there was little support for improvements in other types maladaptive metacognitions 
(negative metacognitive beliefs, cognitive confidence, cognitive self-consciousness and need 
to control thoughts).  Results also found that although group data showed a decrease in 
patients use of worry as a thought control strategy following MCT, individual analysis 
showed no clinically significant changes in this outcome measure. Moreover, there were no 
changes observed at either the group or individual level in patients use of punishment as a 
thought control strategy after MCT. After receiving MCT intervention, patients also showed 
reductions in depressive symptoms, worries and rumination levels at both the group level and 
individual level. Overall the current study shows promising results for the use of adapted 
metacognitive therapy as an intervention for patients with anorexia nervosa.  
 






Anorexia nervosa is an eating disorder whereby individuals engage in a wide variety 
of behaviours to help them lose a significant amount of weight in order to achieve ‘thinness’ 
(American Psychiatric Association, 2013). These individuals resort to starvation type diets in 
which they closely monitor and restrict the amount of calories and types of food they 
consume; these diets may be accompanied by harmful behaviours such as binging/purging 
and over exercising to the point of exhaustion (American Psychiatric Association, 2013). The 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, outlines specific criteria 
which need to be met before an individual can be diagnosed with anorexia nervosa.  
Firstly, a health professional such as a clinician, psychiatrist or doctor must assess 
whether the individual’s food intake is below the expected daily nutrition requirement, 
resulting in substantially low body weight.  The World Health Organisation uses the Body 
Mass Index (BMI) to calculate if an individual is underweight (APA, 2013). The BMI is also 
relied upon to measure the severity of the individual’s eating disorder by using the following 
BMI categories: BMI > 17kg/m (Mild), BMI = 16 -16.99kg/m (Moderate), BMI = 15 – 
15.99kg/m (Severe) and BMI < 15kg/m (Extreme). Secondly, in addition to their 
significantly low body weight, the individual must have an extreme ongoing fear of increased 
weight or must engage in behaviour which prevents them from gaining any body weight 
(APA, 2013). Finally, the clinician must make an assessment as to whether the individual has 
a distorted perception of their body; whether their self-worth is based on how they view their 
own body image; or whether the individual is ignorant about the health risks associated with 
being significantly underweight (APA, 2013). If an individual meets these three criteria’s, a 
diagnosis of anorexia nervosa may be appropriate.  
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Anorexia nervosa is divided up into two different subtypes: restrictive, which occurs 
when the individual’s behaviour is limited to calorie restrictions in order to lose body weight 
and the binge-eating/purging subtype, whereby within the past 3 months the individual’s 
attempt to restrict food leads to a loss of control through a binge-eating episode followed by 
the compensatory behaviour of vomiting (purging) after the binge in order to avoid weight 
gain (APA, 2013). Although the binge-eating/purging subtype seems analogous to another 
eating disorder called Bulimia Nervosa, in which individuals repeatedly binge and purge in 
an effort to lose weight, the hallmark feature of anorexia nervosa which distinguishes it from 
these other eating disorders is that individuals have dangerously low body weight as a result 
of their dysfunctional eating patterns and behaviours (APA, 2013). 
Eating disorders such as anorexia nervosa often develops at a young age, occurring 
when individuals are in the transition period of child to adulthood (APA, 2013). The journey 
into adulthood is accompanied by major life transitions, such as high school graduation, 
starting tertiary education, moving out of home or looking for employment; these events are 
often stressful and coincide with the development of disorders such as anorexia nervosa 
(APA, 2013). Individuals living in countries where there is a societal pressure to be ‘thin’ are 
also more at risk of developing an eating disorder (APA, 2013; Culbert, Racine & Klump, 
2015). It is estimated the gender ratio for this eating disorder is 10 females:1 male (APA, 
2013).  
Recently it has been found that anorexia nervosa has a 0.3-0.4 prevalence rate and 
around eight new cases of anorexia nervosa out of 100 000 people are being diagnosed each 
year (APA, 2013; Hoek & van Hoeken, 2003). Many of these new cases of anorexia nervosa 
are likely to be adolescents or in the early stages of their adult life (APA, 2013). Despite the 
low prevalence rates of anorexia nervosa compared to other disorders in the DSM-5, anorexia 
nervosa is considered to be one of the most dangerous disorders because of its high mortality 
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rates (Chesney, Goodwin & Fazel, 2014). These high mortality rates are due to the fact that 
individuals diagnosed with anorexia often experience medical complications as a result of 
their seriously low body weight (APA, 2013). Individuals who struggle with anorexia often 
suffer from malnutrition; the lack of nutrition in the body may lead to liver damage, organ 
failure and weakened bone density, all of which increases the risk of mortality (APA, 2013; 
Gaudiani, Sabel, Mascolo & Mehler, 2012). Individuals with anorexia nervosa also have a 
heightened risk of engaging in suicidal behaviours due to psychological distress (APA, 
2013). Hence, the literature and research have highlighted the need for an effective form of 
intervention to treat individuals diagnosed with anorexia nervosa, especially those who have 
struggled with eating disorder for years as they continue to have recurring episodes of 
anorexia nervosa throughout their life.  
 In an effort to gain a better understanding of the issues and difficulties which arise in 
the treatment of individuals with anorexia nervosa, a review of the different interventions 
currently being utilised in hospitals, clinics and outpatient treatment centres will be provided 
in the following sections.  
 
The effectiveness of current interventions utilised in the treatment of individuals diagnosed 
with anorexia nervosa 
The National Institute for Health and Care Excellence (NICE, 2017) has 
recommended that psychological interventions such as individual eating-disorder-focused 
cognitive behavioural therapy (CBT-ED), specialist supportive clinical management (SSCM) 
and Maudsley Anorexia Nervosa Treatment for Adults (MANTRA) should be used to treat 
anorexia nervosa. The effectiveness of these interventions will be explored below.  
The research on finding an effective treatment for individuals with anorexia has used 
a wide array of different types of interventions, as well as modifying pre-existing 
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interventions for anorexia in an attempt to improve long term outcomes for this seemingly 
treatment-resistant disorder. One such study investigated the use of cognitive behavioural 
therapy (CBT) with virtual reality in treating patients with eating disorders, such as anorexia 
nervosa, bulimia nervosa and EDNOS (Marco, Perpina & Botella, 2013). In the Marco et al., 
(2013) study patients received either a standalone standard CBT for Eating Disorders 
Treatment (SEDT) or SEDT combined with virtual reality (VR) which had several aims one 
of which was to assist them to become aware of their distorted perceptions of their own body 
image (SEDTBI). Marco, Perpina & Botella ( 2013) showed that compared to SEDT, the 
CBT combined with VR treatment was the more efficacious treatment for eating disorders as 
patients in this group showed more marked reductions in eating disorder symptoms after 
treatment was complete and these treatment effects were still present 1 year later. However, 
out of 34 patients with eating disorders, this study only had 5 patients who were diagnosed 
with anorexia nervosa (Marco et al., 2013). Furthermore, it was not clear how long these 
individuals had been struggling with anorexia or whether any of these individuals with AN 
dropped out from the study. These factors make it hard to conclude whether CBT combined 
with VR is an effective treatment for anorexia nervosa  
In another longitudinal study which looked specifically at CBT intervention for 
individuals diagnosed with either anorexia nervosa or subthreshold anorexia found that at the 
3 year follow up, only 33% of the participants no longer met diagnosis for anorexia nervosa, 
which is concerning considering some of these participants did not initially meet full criteria 
for anorexia nervosa (Ricca, Castellini, Sauro, Mannucci, Ravaldi, Rotella & Faravelli, 
2010). In contrast, other CBT interventions have been used by researchers in an attempt to 
treat patients with severe anorexia nervosa who had been struggling with their eating disorder 
for 7 or more years of their life (Touyz, et al., 2013). The researchers found that both 
cognitive behavioural therapy which had been specifically adapted to treat anorexia nervosa 
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(CBT-AN) and specialist supportive clinical management (SSCM) were effective in reducing 
symptoms of anorexia nervosa (Touyz et al., 2013). Primary measures such as the Eating 
Disorder quality of Life instrument (EDQOL) was used to measure the quality of life of 
individuals struggling with anorexia by examining their psychological, physical, cognitive 
and work life functions. Results showed marked improvements in individual’s quality of life 
after receiving treatment, (Effect size post treatment: 0.73 (CBT); 0.92 (SSCM)). 
Furthermore, these treatment gains were maintained during a 12 month follow up (Effect 
size: 0.84 (CBT); 1.11 (SSCM)) (Touyz et al., 2013). However, although patients in this 
study showed improvements in their eating disorder psychopathology, it is unclear whether 
patients achieved full remission of their eating disorder.  
 Other studies which used cognitive behavioural therapy for maintaining the treatment 
effects for anorexia nervosa, cited that 65% of patients who received CBT had sustained 
remission (Carter, McFarlane, Bewell, Olmsted, Woodside, Kaplan & Crosby, 2009). 
However, this study had high attrition rates, as a large proportion of patients did not complete 
the year long CBT treatment. This was acknowledged by the authors who agreed that the 
sheer number of participants who did not complete treatment was concerning, thus 
highlighting a main issue of attrition when it comes to treating patients with anorexia nervosa 
(Carter et al., 2009).  
Apart from CBT, studies have used other forms of intervention for anorexia nervosa 
such as cognitive remediation therapy and the Maudsley Model of Anorexia Nervosa 
Treatment for Adults. A study by Lock, Agras, Fitzpatrick, Bryson, Jo & Tchanturia, 2013 
used cognitive remediation therapy in an attempt to provide an effective intervention for 
individuals diagnosed with anorexia nervosa that would minimise the high dropout rates 
usually observed in anorexia nervosa interventions. This study uses cognitive remediation 
therapy (CRT) in which patients engage in cognitive exercises which may assist them in their 
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daily lives by changing the way they think and evaluate themselves. Those diagnosed with 
anorexia nervosa were placed in one of two conditions where they received either; CRT 
followed by CBT, or standalone CBT intervention. Although the results of the study initially 
showed lower drop out rates in the CRT group (13%) than the CBT group (33%) by the time 
both groups had completed treatment, more patients in the CRT group had dropped out to the 
point where there was no difference in drop-out rates between treatment groups (Lock et al., 
2013).  
The Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA) has 
been used to treat patients with anorexia nervosa by addressing maladaptive cognitions and 
unhealthy social relationships which maintain the disorder  (Schimt et al., 2015). Schimt et 
al., 2015 conducted a randomised controlled trial whereby patients with anorexia nervosa 
were placed in one of two intervention groups; MANTRA or the Special Supportive Clinical 
Management (SSCM). Those in the SSCM group received ongoing therapy whereby the 
therapist provides support and psychoeducation to those with anorexia nervosa. In terms of 
whether patients received and maintained full remission 12 months after beginning treatment, 
the Schimt et al., (2015) study showed that only 16.33% of patients who received SSCM and 
22.41% of patients who received MANTRA intervention achieved a BMI >18.5 kg/m² as 
well as an eating disorder examination global score of < 2.77, which indicates that a majority 
of patients in the study did not maintain a full recovery when they were assessed 12 months 
after starting treatment. This only demonstrates the difficulties in treating adults with 
anorexia nervosa and emphasises that anorexia nervosa is a highly treatment-resistant 
disorder. Furthermore, it should be noted that this study included patients diagnosed with 
EDNOS whose BMI was 18.5kg/m as part of their trial.  
Overall research studies have found limited evidence for an effective way of treating 
anorexia nervosa in adults. Researchers have encountered many complications when it comes 
OPEN TRIAL OF METACGONTIVE THERAPY FOR ANOREXIA NERVOSA 
 
 8 
to treating anorexia nervosa as clinicians have to contend with high levels of patient drop-
outs during treatment and low remission rates.  Fairburn (2005) conducted a review of 
randomised controlled trials (RCTs) which compared and contrasted different types of 
interventions for treatment of anorexia nervosa. In regards to the interventions available for 
adolescents with anorexia nervosa, Fairburn, (2005) conceded that despite the lack of RCT’s 
conducted in this field, research suggests that family based therapy was effective in treating 
anorexia nervosa in adolescents. However, his review indicated a lack of efficacious 
interventions targeting anorexia in adults. It was postulated that this was due to the long-term 
consolidation of maladaptive processes which maintain eating disorder symptoms in adults, 
as they are more likely to have experienced longer bouts of symptoms of anorexia than 
adolescents (Fairburn, 2005).  
Recent reviews analysing RCTs such as cognitive behavioural therapy, family 
therapy, and cognitive analytic therapy used to treat anorexia have found that there is a lack 
of research demonstrating the effectiveness of these interventions in treating adults who have 
persistently struggled with anorexia nervosa for years (Hay, Touyz & Sud, 2012). Hence, 
there has been an increase in the number of open trials being conducted to review new 
interventions which could be used to treat adults who have an ongoing, recurring diagnosis of 
anorexia nervosa (Hay et al., 2012). An intervention that may be efficacious in treating adults 
with anorexia nervosa is metacognitive therapy. However, before evaluating the usefulness of 
metacognitive therapy (MCT) as an intervention for anorexia nervosa, it is important to draw 
the distinction between CBT and MCT.  
 
The differences and similarities between Cognitive therapy and Metacognitive therapy 
 Cognitive behavioural therapy, is based on the notion that an individual’s core belief 
of being ‘unlovable’ or ‘unworthy’ causes them to develop assumptions and rules which they 
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must follow such as “If I ask for help, I’ll be seen as incompetent” (Beck, 2011, p. 364) 
These underlying assumptions or intermediate beliefs impact the way in which the individual 
views themselves, the world and the future, they give rise to automatic thoughts, which are 
thoughts that occur spontaneously as the individual navigates their way through life (Beck, 
2011). If an individual has an underlying core belief of being ‘unworthy’, it is most likely 
that they have negative automatic thoughts occurring in their daily lives, such as “I can’t do 
this” (pg. 151 Beck, 2011).  
 Cognitive behavioural therapy is based on the assumption that psychological distress 
is caused by negative maladaptive cognitions and dysfunctional beliefs (Wells, 2009). 
Cognitive theorists propose that treatment should focus on targeting negative cognitions and 
changing negative interpretations of a situation into more balanced realistic thoughts (Beck, 
2011, Wells 2009); Metacognitive theorists on the other hand believe that changing the 
particular style of the individual’s thinking processes which occurs at the metacognitive 
stages of higher order processing is what is required (Wells, 2009). Therefore, instead of 
evaluating negative automatic thoughts by examining the evidence for and against it, which is 
a technique used by cognitive theorists; metacognitive therapy helps the individual to change 
their response to their negative automatic thoughts as it is this response rather than the 
thoughts in itself that cause the psychological distress (Wells, 2009).  
 
The Metacognitive Model  
Metacognitions 
Metacognition can be thought of as Fisher and Wells (2009) describes more 
eloquently “cognition applied to cognition” (p. 3), which essentially means to be aware of 
one’s own higher order cognitive processes and how it can influence the way we think about 
things such as situations or events. Metaphorically, metacognitions are the drivers which 
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choose which route to take, which in turn determines how our cognitions are interpreted and 
processed (Wells, 2009).   
 
Self-regulatory Executive Function model 
 In order to understand the role of metacognition and the different ways it can 
influence an individual’s psychological wellbeing, the Self-Regulatory Executive Function 
model which underpins MCT will be explained (Fisher & Wells, 2009; Wells, 2009; Wells, 
2000). The Self-Regulatory Executive Function model (S-REF) has three distinct levels of 
cognitive processing. The literature on the S-REF model has different names to describe each 
of the three levels, for the purpose of simplicity and consistency, the levels proposed in the 
Wells (2009) S-REF model will be used.  
1. Low-Level Processing 
The first level is called the Low-level processing stage. This lower-level processes 
information entering the S-REF automatically, it does not require the conscious 
awareness of the individual to process stimuli from the outside world (Wells, 2009; 
Wells, 2000; Wells & Matthews 1996).  
2. Online Conscious Processing/Cognitive Style 
The second level of information processing within the S-REF, is online controlled 
processing. At this level stimuli are consciously appraised and strategies are 
implemented with the “aims to reduce any discrepancy between current status and 
target status” (Matthews & Wells, 2003, p. 129).  When a persistent thinking style 
‘cognitive attentional syndrome’ is implemented this can lead to psychological 
distress (Wells 2009; Fisher & Wells, 2009) 
3. Meta-system 
OPEN TRIAL OF METACGONTIVE THERAPY FOR ANOREXIA NERVOSA 
 
 11 
The third level of the S-REF, involves metacognitions and is known as the meta-
system. The meta-system contains metacognitive knowledge and contains a model for  
ongoing cognitive processes occurring at the lower stages of the S-REF system. Thus, 
metacognitive knowledge is used to guide and monitor the individual’s cognitive 
processing style (Wells, 2009; Wells 2000) 
These three levels of the S-REF model interact with each other in various ways as 
information is being processed. As previously stated, metacognitive knowledge can influence 
the way in which individuals process and respond to a situation. (Fisher & Wells, 2009; 
Wells 2000; Wells, 2009). When someone holds theories or information about their thinking 
this is known as metacognitive knowledge (Wells, 2000; Wells, 2009). Metacognitive 
knowledge is made up of declarative beliefs and procedural beliefs (Wells 2000; Wells, 
2009). Declarative beliefs are also known as explicit beliefs, as individuals are consciously 
aware of them. For example, an individual may have the belief that “worrying can damage 
my body”  (Wells, 2009 p. 16) (Wells, 2000; Wells 2009). Thus, declarative beliefs are the 
individual’s evaluation of their own thinking (Wells, 2000). Procedural beliefs are implicit as 
individuals may not be aware of them. These implicit beliefs are plans which assist in the 
guidance of thinking, (Wells, 2009). These plans involve memory retrieval, allocating 
attention, and biases (Wells, 2000; Wells, 2009; Wells & Mathews, 1996).  
Metacognitive strategies such as suppression or preservation reflect the ways in which 
an individual tries to suppress or control their own thoughts, often in an effort to reduce 
psychological distress. Unfortunately, metacognitive strategies such as suppression, worry or 
distraction are usually ineffective and attempts to control thoughts and may serve to maintain 
the individual’s distress (Wells, 2009). Metacognition is also comprised of metacognitive 
experiences (Wells, 2000). Metacognitive experiences refers to appraisals, interpretations and 
feelings about cognitions (Wells, 2009; Wells, 2000). Wells (2009) illustrates that when a 
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person worries about their worries, or has a ‘feeling of knowing’ which is a subjective 
feeling, these are both examples of metacognitive experiences. When cognitions and feelings 
are negatively judged by individuals, these metacognitive experiences can play a role in the 
processes of psychological distress (Wells, 2009).   
 
Cognitive Attentional Syndrome 
Now that the components which comprise the S-REF model have been explained, it is 
important to show how within the model, a particular style of thinking called the cognitive 
attentional syndrome (CAS) can lead to psychological distress in individuals (Wells, 2000).  
Cognitive attentional syndrome (CAS) is a perseverative style of thinking which is comprised 
of worry and rumination, maladaptive coping behaviours and fixating attention on threat 
(Wells, 2009; Wells & Fisher, 2015). Both worry and rumination involves persistent 
conceptual processing of information. Individuals who worry are focused on any potential 
future threats, thus they become fixated on answering questions of ‘What if?’, On the other 
hand, rumination is usually focused on past events and questions of ‘Why me?’ (Fisher & 
Wells, 2009; Wells, 2009). However, failure to find answers to these questions can result in 
persistent engagement in these ruminating and worry processes which can exacerbate feelings 
of anxiety and depression (Fisher & Wells, 2009; Matthews & Wells, 2003; Wells, 2009). 
The processes involved in worrying and ruminating also require the usage of attentional 
resources, which could instead have been used for more adaptive ways of responding to 
negative information, such as external based problem solving strategies (Wells, 2009; Wells 
2000; Matthews & Wells 2003). Moreover, continued usage of rumination and worrying 
results in the strengthening of plans to utilise these conceptual processes as response to 
negative information in the future (Wells, 2000; Wells, 2009).   
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The CAS also involves the focus of attention on threat through the use of threat 
monitoring strategies (Wells & Fisher, 2015; Fisher &. Wells, 2009). Individuals may place 
their attentional focus on stimuli which are threatening, this includes negative thoughts, 
emotions and sensations in the body (Fisher & Wells, 2009). This threat monitoring strategy 
is problematic in psychological disorders as Wells & Fisher (2015) states that when those 
struggling with depression constantly monitors their concentration and bodily sensations for 
signs of depression, this increases their sense of danger.  
Maladaptive coping behaviours are also part of CAS. Individuals may engage in 
maladaptive coping behaviours such as reassurance seeking, alcohol use, thought suppression 
or avoidance. For example, individuals with depression may decrease activity levels because 
they have the metacognitive belief that “I must reduce my work level when feeling sad 
because my mind can’t take it” (Wells, 2009, p. 219). However, these behaviours are 
unhelpful as avoidance precludes individuals from obtaining information which could 
disconfirm their beliefs (Wells, 2009). Moreover, as previously stated the use of thought 
suppression strategies usually produce unsuccessful results (Wells, 2009).  
When individuals become locked into the CAS style of thinking they are engaging in 
a persistent form of prolonged processing of negative intrusions which leads to distress; those 
with psychological disorders may find it difficult to switch out of this problematic thinking 
style which highlights the lack of control over flexibility of responses (Wells, 2009).    
 
The role of metacognitive beliefs in developing and maintaining the CAS cycle 
Many people have negative thoughts or beliefs about themselves, however, not 
everyone experiences psychological distress due to these negative cognitions (Wells & 
Fisher, 2015). Individuals who are able to respond flexibly to negative cognitions experience 
only brief periods of aversive emotions (Wells & Fisher, 2015; Wells, 2009). Whereas, 
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individuals who engage in maladaptive thought processing styles such as rumination, 
worrying, threat awareness and avoidance become trapped in an inflexible prolonged 
maladaptive style of thinking which leads to psychological distress (Fisher & Wells, 2009).  
 
Wells (2009) identified two different types of metacognitions; positive and negative. 
Positive metacognitive beliefs refer to the belief an individual has that their maladaptive 
cognitive processes of rumination/worry, threat awareness and avoidance are helpful coping 
strategies (Fisher & Wells, 2009). Therefore, positive metacognitive beliefs such as 
“Thinking about the causes of sadness will help me prevent it” (Wells, 2009, p. 200) only 
serve to develop and perpetuate the negative style of thinking (CAS) which creates ongoing 
psychological distress (Fisher & Wells, 2009; Wells, 2009).  
Negative metacognitive beliefs also play a role in the development of CAS, as 
individuals may start to believe that their thoughts are somehow dangerous and 
uncontrollable (Fisher & Wells, 2009; Wells, 2009). For instance, beliefs such as; “my 
thinking has changed; I’m no longer in control” (Wells & Fisher, 2015, p. 138) further 
perpetuates the CAS as individuals view worrying and rumination processes as 
uncontrollable, they regard these processes as a symptom of their psychological disorder as 
opposed to viewing them as voluntary strategies (Wells & Fisher, 2015; Wells, 2009).    
 
Metacognitive Therapy 
 Metacognitive Therapy was developed by Adrian Wells as an intervention to treat 
those who were struggling with emotional disorders. It is used to alleviate psychological 
distress in individuals by modifying maladaptive metacognitive beliefs and targeting CAS. It 
was theorised that once the metacognitive beliefs were effectively challenged, CAS is 
removed and individuals are taught to adopt more adaptive flexible ways of responding to 
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negative information, this will lead to a reduction in psychological distress  (Fisher & Wells, 
2009; Wells, 2009). The basic components of MCT will briefly be outlined below.  
Before working on implementing MCT intervention strategies in collaboration with 
the client, the therapist must first evaluate and identify which specific maladaptive cognitive 
processes are being used to maintain the client’s psychological distress (Wells, 2009). Once 
the therapist identifies whether the client engages in worrying or rumination processes, the 
client is made aware of the mechanisms which maintain their disorder and how MCT works 
to change them (socialisation). Throughout the MCT therapy sessions, the therapist uses 
socratic dialogue to identify the client’s own metacognitive beliefs and how the client 
interacts or responds to their own cognitions (Wells, 2009).  
One of the main components of MCT intervention is helping the client shift to a 
metacognitive mode of perceiving, where they are able to view their thoughts as a separate 
entity from themselves through the processes such as detached mindfulness tasks (Fisher & 
Wells, 2009). A variety of strategies are implemented to break the CAS cycle and reduce 
maladaptive metacognitive processes. These include attention training techniques, detached 
mindfulness tasks, worry/rumination postponement and challenging positive and negative 
metacognitions which all aim to teach patients different more flexible ways of responding to 
thoughts rather than using worrying or rumination (Wells, 2009). The positive and negative 
metacognitive beliefs of the client are modified through the use of therapy techniques such as 
verbal reattribution and behavioural experiments. (Wells, 2009). For example, a therapist 
may use verbal reattribution to help the patient to re-examine their belief that worrying or 
rumination is helpful for problem solving and seeking answers. A therapist will also 
challenge the patient’s belief that worrying or rumination is dangerous or uncontrollable 
through the use of behavioural experiments. For example, the patient is told to worry as much 
as possible for a period of time to prove that worrying will not cause hallucinations, nor is it 
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physically harmful (Wells, 2009). As a final step, relapse prevention strategies are put into 
place in order to prevent clients from engaging in maladaptive perseverative thinking styles 
in the future (Wells, 2009).  
 
The efficacy of MCT as an intervention for treating psychological disorders 
Previous research indicates that MCT can be a useful intervention for various 
psychological disorders such as generalised anxiety disorder, obsessive compulsive disorder, 
depression and other anxiety disorders (Johnson, Hoffart, Nordahl & Wampold, 2017; van 
der Heiden, Muris & van der Molen, 2012; van der Heiden, Rossen, Dekker, Damstra & 
Deen, 2016; Wells et al., 2012). For example, Wells et al., (2012) conducted a trial which 
evaluated the effectiveness of MCT for patients suffering from treatment-resistant depression. 
In this trial, patients who had unsuccessfully attempted to treat their depression, either 
through some form of therapy or antidepressant, were recruited for MCT intervention. These 
patients received a brief MCT intervention (8 sessions) with a qualified clinician. The results 
found that depending on the recovery criteria more than half of the patients who finished the 
treatment program achieved recovery (Beck Depression Inventory (BDI) ES: 1.65). 
Furthermore, these improvements were maintained at the 1 year follow up (BDI ES: 2.29) 
(Wells et al., 2012). Hence this study demonstrates that when it comes to treating persistent 
cases of depression MCT may be a useful intervention.   
Research studies have also utilised randomised controlled methodology to examine 
whether MCT is as efficacious as other standardised interventions such as cognitive 
behavioural therapy in treating anxiety disorders (Johnson, Hoffart, Nordahl & Wampold, 
2017). Patients who were diagnosed with social phobia, post-traumatic stress disorder, or 
panic disorder with or without agoraphobia were recruited for this study. Furthermore, the 
majority of patients in this study not only had a primary diagnosis of an anxiety disorder but 
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they also met criteria for a secondary DSM-IV disorder. These patients had also previously 
received some sort of psychological treatment for their anxiety disorders, but were 
unresponsive to these interventions. Once patients agreed to participate in this study, they 
were randomly placed in one of the two intervention groups, CBT or MCT treatment group. 
Patients in each intervention group received individual therapy sessions with either a clinical 
psychologist or psychiatrist. The findings indicated that patients in the MCT group recovered 
faster than those in the CBT group after treatment (Beck anxiety inventory ES: d =  1.0; Penn 
State Worry Questionnaire ES: d = 0.83). In the months after treatment completion, patients 
in the CBT group showed greater recovery rates but at the 12 month follow up there were no 
differences in the efficacy of treatment between the MCT and CBT group (Johnson, Hoffart, 
Nordahl & Wampold, 2017).  It is important to note that although patients from both 
intervention groups received a similar number of therapy sessions, those in the CBT group 
had longer individual sessions of 70 minutes compared to patients in the MCT group who 
received 50 minute sessions. Therefore, it appears that MCT is a more efficient form of 
treatment for patients with comorbid anxiety disorders as they received shorter therapy 
sessions and had faster recovery rates than those receiving CBT intervention (Johnson et al., 
2017). Furthermore, it appears that MCT is a suitable transdiagnostic treatment for those 
diagnosed with 2 or more psychological disorders.  
Another study examined the utility of MCT as a transdiagnostic treatment for 
individuals diagnosed with comorbid depression (Hjemdal et al., 2017). This study was an 
open trial in which patients with a primary diagnosis of major depression and a secondary 
comorbid disorder (anxiety disorders or avoidant personality disorder) received MCT 
intervention. The MCT intervention used to treat patients in this trial was specifically 
designed to target depression symptoms. Due to the nature of an open trial, only 10 patients 
were recruited for the study. Patients received one-to-one MCT intervention with an 
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experienced clinician. By the end of the intervention, 9 patients met the threshold for 
recovery based on their improved BDI outcomes  (BDI: Hedges g = 2.89). Furthermore, at 
the 6 month follow-up period, seven out of ten patients met the recovery criteria (BDI: 
Hedges g = 2.40).  Despite the small sample size, the findings of this open trial indicated that 
MCT is a highly efficacious treatment for comorbid depression (Hjemdal et al., 2017).  
Further studies evaluated the efficacy of MCT in treating generalised anxiety disorder 
against the efficacy of other interventions such as the intolerance of uncertainty therapy (van 
der Heiden, Muris & van der Molen, 2012). This study recruited patients diagnosed with 
generalised anxiety disorder and placed them in one of three treatment groups: MCT group, 
intolerance of uncertainty therapy (IUT) group or delayed treatment (DT) group. The delayed 
treatment group served as a control for the other two interventions. Patients in the MCT and 
IUT intervention group received individual therapy sessions with a psychologist. It was found 
that patients who received MCT had higher remission rates (91%) than patients receiving 
IUT intervention (80%), Patients from both therapy groups continued to improve after post-
treatment, as 93% of patients who received MCT and 90% of those who received IUT were 
in remission (van der Heiden, Muris & van der Molen, 2012). Hence, results of this study 
indicate that compared to IUT intervention, MCT had quicker improvements in patients with 
GAD and was more efficacious than IUT in treating GAD (van der Heiden, Muris & van der 
Molen, 2012).  
Overall these studies indicate that MCT is an effective intervention for treating 
different psychological disorders, as it produces faster recovery in patients with 
psychological distress and can also be used transdiagnostically as an intervention for 
individuals struggling with comorbid psychological disorders. Hence, MCT may be a 
promising form of intervention for individuals diagnosed with anorexia nervosa, which has 
proven to be a difficult disorder to treat. 




Worry, rumination and eating disorders 
 Previous research has found that in undergraduate female students, worry can predict 
the ‘drive for thinness’ which is associated with a person’s drive for weight loss (Sala & 
Levinson, 2016). In terms of the clinical population, studies have indicated that in patients 
diagnosed with an eating disorder who have previously received treatment, worry can predict 
patients’ eating disorder symptomology after treatment (Fewell, Levinson & Stark, 2017). 
Moreover, research has found that patients with eating disorders (anorexia nervosa and 
bulimia) have higher levels of worry compared to those without an eating disorder (Sassaroli 
et al., 2005). Studies examining the content of worry for individuals with eating disorders 
have found that their initial worries focused on themes of weight and shape concerns (weight 
gain), purging behaviours and fear of relapse (course of illness), but as individuals continued 
to catastrophise these worries evolved into content related to interpersonal relationships, 
experience of negative emotion and negative perception of self (Sternheim et al., 2012).  
Past research indicates that not only do patients with anorexia nervosa have raised 
levels of worry and rumination, but that even after taking into account anxiety and 
depression, these repetitive negative thinking styles predicted patients’ eating disorder 
symptomology (Startup et al., 2013). Interestingly, Sternheim et al., (2012) found that there 
were no significant differences in worry between individuals with eating disorders and 
controls when depression was taken into account. However, these two studies have quite 
different clinical samples. When Sternheim et al., (2012) recruited patients with eating 
disorders, they purposely excluded individuals who had a comorbid clinical diagnosis of 
depression or anxiety. Whereas, Startup et al., (2013) included individuals with anorexia 
nervosa who also had comorbid anxiety or depression in their clinical sample. Hence, these 
differences in their results may be due in part to their clinical sample.  
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 Studies have also indicated that in patients diagnosed with an eating disorder, 
increased repetitive negative thinking (rumination/worry) was found to be predictive of 
increased eating disorder behaviours as patients were likely to weigh themselves more often 
(Sala, Brosof & Levinson, 2019). Research has shown that when patients with eating 
disorders were exposed to a sad video clip they engaged in more maladaptive emotional 
regulation strategies such as rumination and suppression compared to those without eating 
disorders (control group) (Naumann, Tuschen-Caffier, Voderholzer & Svaldi, 2016). 
Moreover, both rumination and suppression strategies were predictors of eating disorder 
symptomology (Naumann et al., 2016). Studies have also found that when individuals with 
eating disorders were purposefully exposed to images of thin models and were subsequently 
told to engage in rumination or acceptance based strategies to regulate their emotions, those 
who utilised rumination as an emotional regulation strategy experienced a rise in body-
dissatisfaction levels (Naumann, Tuschen-Caffier, Voderholzer, Schafer & Svaldi, 2016).  
 Previous research compared the use of other emotion regulation strategies such as 
distraction and rumination in patients with eating disorders (Naumann, Tuschen-Caffier, 
Volderholzer, Caffier & Svaldi, 2015). This study found that after inducing emotions of 
sadness in patients, the use of rumination as a strategy to regulate emotions increased desire 
to abstain from eating in patients with anorexia nervosa, whereas no such increase in the 
desire to abstain from eating was observed in patients with anorexia who utilised distraction 
strategies (Naumann et al., 2015).  
Metacognitive beliefs of individuals with eating disorders 
Vann, Strodl & Anderson (2013) proposed a transdiagnostic metacognitive model of 
eating disorders, based on Wells’ own metacognitive model. Through the use of qualitative 
research Vann et al., (2013) developed the metacognitive model to show how eating disorder 
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psychopathology is developed and maintained, with the practical implication that this can 
inform future research investigating the use of metacognitive therapy as treatment for eating 
disorders. In Vann et al., (2013) qualitative study, researchers interviewed individuals who 
were diagnosed with an eating disorder, with questions about their metacognitions, coping 
behaviours and attentional focus. In Vann’s et al’s (2013) study, participants endorsed 
positive metacognitive beliefs such as; “I need to focus and perseverate on my negative 
thoughts to protect me from losing control of my eating, because if I lose control of my 
eating I will become fat and worthless” (Vann et al., 2013 p.5). These positive metacognitive 
beliefs lead to activation of the CAS where perseverative negative thinking 
(worry/rumination) and attentional bias about body image/food/eating occurs. Negative 
metacognitive beliefs are also activated. In the Vann et al., (2013) study three types of 
negative metacognitive beliefs emerged; “Strong emotions and negative thoughts are 
uncontrollable and awful” (Vann et al., 2013, p.6) , “Strong emotions are confusing – I don’t 
know what I am feeling or what to do about the feeling” (Vann et al., 2013, p.6) and “All 
negative thoughts are bad, wrong or abnormal and need to be addressed” (Vann et al., 2013, 
p.6). Positive metacognitive beliefs about coping strategies are also activated. Individuals 
engage in maladaptive coping strategies to deal with their distress; these coping strategies 
include suppression/avoidance of negative emotions or thoughts, restricting food intake in an 
attempt to control ruminations/worries and negative emotions, binge eating to distract from 
negative thoughts/emotions, purging and social avoidance.  
Previous research studies have also found that those diagnosed with AN have 
underlying negative metacognitions (McDermott & Rushford, 2011). McDermott and 
Rushford (2011) reported that the CAS cycle was present in patients with anorexia nervosa as 
seen reflected in their MCQ-30 subscale scores, where those with AN have shown more 
negative metacognitions (uncontrollability of worry), high cognitive self-consciousness, low 
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cognitive confidence and held more beliefs about the importance of controlling one’s 
thoughts compared to controls.  
Other studies have also reported similar findings where patients’ with eating disorders 
had a greater degree of maladaptive metacognitions compared to controls (Olstad, Solem, 
Hjemdal & Hagen, 2015). Moreover, it was found that dysfunctional metacognitions was 
correlated with eating disorder symptomology. In particular the metacognitions of ‘need to 
control thoughts’ MCQ-30 subscale was highlighted as one of the predictors of eating 
disorder symptoms. It was proposed that coping behaviours such as eating disorder 
behaviours may be utilised as a way of controlling ruminations or worries (Olstad et al., 
2015). Studies have found that metacognitive beliefs such as the need to control thoughts and 
positive beliefs about worry predicted patients’ drive for thinness in individuals with anorexia 
nervosa, whereas negative beliefs about worry predicted the drive to be thin in patients with 
atypical anorexia nervosa (Davenport et al., 2015).  
Overall, there is a great deal of evidence that metacognitive processes are relevant to 
eating disorders, thus the present study explores the usefulness of adapted MCT for patients 
struggling with anorexia nervosa.  
Present Study 
The present study aims to explore the effectiveness of modified MCT for patients 
diagnosed with either anorexia nervosa or atypical anorexia nervosa. This modified MCT 
trial for those diagnosed with anorexia nervosa or atypical anorexia nervosa was conducted at 
the South Island Eating Disorders Service (SIEDS) by clinical psychologists. The MCT 
utilised in this open trial originally used to treat major depressive disorder (MDD); however, 
modifications were made to target the symptoms of anorexia nervosa. As previously 
discussed, studies have shown that individuals with anorexia have underlying maladaptive 
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metacognitions about themselves (McDermott & Rushford, 2011). When it came to 
modifying MCT treatment for MDD into an intervention which can be utilised to treat 
patients with anorexia nervosa, clinical psychologists at the SIEDS first provided patients 
with psychoeducation about the consequences of having an eating disorder and how it not 
only affects mental well-being but it also causes internal damage to the body’s system. 
Moreover, patients learnt the importance of eating regular meals. They also received 
information about how their thoughts and behaviours contributed to the maintenance of their 
eating disorders. Aside from psychoeducation, MCT for anorexia nervosa also involved 
monitoring of food intake and weekly weigh ins to keep track of changes in body weight. 
Patients were also referred to a dietician if they required further nutritional advice.  
The aim of this study was to explore whether patients receiving MCT experience a 
positive change in their metacognitions, weight/body mass index, thought control strategies 
and anorexia nervosa (AN) symptoms from pre-treatment to post-treatment.  
It is hypothesised that:  
1. Modified MCT can be successfully used to treat patients with AN. This will be 
evidenced through the following changes: 
A. Patients with AN will have a significant increase in weight and decrease in eating 
disorder symptoms after receiving MCT.  
B. use of modified MCT will result in patients with AN experiencing a decrease in 
their maladaptive metacognitions and unhealthy thought control strategies.  
C. The use of MCT would result in a decrease in worrying and rumination and 
depressive symptoms.  
 
 






Patients were recruited through sequential referrals from general practitioners and 
other mental health services to the South Island Eating Disorder Services (SIEDS) for AN 
treatment. Patients recruited for the trial were aged 16 years or older, with a current, primary 
DSM-V diagnosis of Anorexia Nervosa or Atypical Anorexia Nervosa (patient meets criteria 
for AN, however they are in a normal weight range). Patients who were suicidal, bipolar 1, 
psychotic, substance dependent or had a BMI < 14 were excluded from participating, as these 
patients required inpatient services rather than outpatient treatment.  
A total of twenty-six patients consented to this study and agreed to undergo 10-20 
weekly sessions of metacognitive therapy with a clinician at the SIEDS. However, the data 
from only 12 patients will be included in this study due to patient drop outs and incomplete 
outcome measures. This is shown by the flowchart (Figure 1) 
Figure 1 











Twenty-six patients were 
recruited for the MCT trial 
8 patients did not 
complete the MCT trial 
6 patients were excluded 
due to missing data 
12 patients completed the MCT 
trial 
A total of 14 patients were 
excluded from data 
analysis 





Patients in this open-trial study received metacognitive therapy previously utilised for 
treating major depressive disorder (MDD) which was adapted to target and treat eating 
disorder psychopathology. The instructions for administering MCT were based on the 
guidelines developed by Adrian Wells to treat MDD (Wells, 2009). Patients who were 
sequentially referred to the SIEDS clinic and upon clinical assessment met the requisite 
criteria for inclusion in the study were invited to be a part of the open MCT outpatient trial. 
Patients who agreed to take part in the trial were provided information about the study and 
were asked to sign a consent form (Appendix A and Appendix B). Patients were assigned to 
the clinician trained in MCT who had previously assessed them at intake. There were four 
therapists who carried out the MCT intervention. Therapists were all clinical psychologists 
who were experienced in working with patients with eating disorders. Each therapist received 
training in MCT and were provided with therapy supervision throughout the study. Ethical 
approval was granted for this study (Appendix C).  
Metacognitive therapy for anorexia nervosa 
 As part of the modification to Well’s (2009) MCT, patients at the SIEDS received 
psychoeducation about the impact their eating disorder has on their physical and 
psychological health. They received psychoeducation about the importance of regular eating 
and were provided nutritional guidance. A dietician was also available for those who needed 
further advice about food diet. Patients also learnt about the various perpetuating factors 
which maintain their eating disorders. Patients were also required to monitor their food, 
eating proper meals regularly each day. Their weight was monitored with weekly weigh-in’s 
during their sessions with a clinical psychologist. The goal at the start of treatment was to 
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establish regular eating patterns for the individual to help them gain weight. Clinicians 
incorporated MCT techniques alongside these eating disorder therapy techniques.  
Metacognitive therapy consisted of eight distinct stages, each of which are essential in 
MCT (Wells, 2009). In the first stage of treatment each clinician formed a case 
conceptualisation of their patient (Wells, 2009). Patients were asked to describe a recent time 
where they felt self-conscious about their body-image or their weight. Patients then described 
what sort of thoughts were going through their mind at that time and how long they spent 
ruminating or worrying. A case formulation was developed which included, internal triggers, 
rumination/worrying response, impact of rumination/worrying on emotions, positive 
metacognitive beliefs, negative metacognitive beliefs, maladaptive coping behaviours, eating 
disorder related behaviours. Through the process of socialisation (Wells, 2009), clinicians 
began to explain the case formulation to their patient, helping them understand how 
metacognitive processes caused and maintained their eating disorder psychopathology. This 
included helping patients understand how their ruminations/worries, metacognitive beliefs, 
resulting self-regulatory behaviours and their attempts to suppress their thoughts plays a role 
in maintaining their current state of eating psychopathology.  
Once the patients had an understanding of how metacognitive processes maintain 
their eating disorder they are then taught techniques such as attention training techniques, 
detached mindfulness and rumination/worry postponement exercises that would help them 
exert control and disengage with their worrying/rumination processes (Wells, 2009) (this 
includes worrying/ruminating about their eating, shape and weight). The aim of attention 
training techniques is to increase attentional flexibility meaning that individuals can exercise 
control over their attention, so that they do not become tied up into perseverative conceptual 
thinking patterns such as worrying or ruminating (Wells, 2009). Detached mindfulness 
exercises are also implemented to teach patients a different way of relating to their thoughts; 
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in detached mindfulness exercises, patients are taught to detach themselves from inner events 
(thoughts) and becoming a passive observer of these inner events; thus, when a negative 
thought or trigger enters their mind they are told to refrain from conceptually analysing 
(rumination/worrying) the thought (Wells, 2009). Detached mindfulness exercises can be 
used alongside rumination/worrying postponement where patients are then taught to refrain 
from ruminating or worrying about a trigger until a specific time later in the day (Wells, 
2009).  
The next stage of therapy consisted of further challenging patients’ negative 
metacognitive belief that their rumination or worry are uncontrollable (Wells, 2009). 
Clinicians used verbal strategies to provide evidence against the idea that rumination/worry 
were uncontrollable or dangerous (Wells, 2009). Experiments were also conducted to 
challenge the patients beliefs that they cannot control their ruminating or worrying. Clinicians 
used strategies such as advantages-disadvantages analysis, questioning the evidence and 
rumination/worrying experiments to challenge the patients’ belief that ruminating/worrying 
about an issue will help them solve the problem (Wells, 2009). Instead of relying on the use 
of worrying or ruminating which leads to distress, clinicians helped the patients explore 
adaptive ways of acquiring positive outcomes. Patients were taught to utilise skills of 
problem solving, preparing and planning as opposed to engaging in worrying or ruminating, 
they were also taught to reflect instead of ruminate on issues.  
As part of relapse prevention, patients were required to continue to practice their 
newly learnt strategies to control their rumination/worrying processes (Wells, 2009). In order 
to avoid relapses, new processing plans were put into place whereby patients identified 
triggers of rumination and worrying and helpful responses (thinking style, behaviours, 
attentional focus) for dealing with these triggers (Wells, 2009).   
 





Information regarding patient’s age, sex and age of onset when first diagnosed with AN was 
collected by a member of the clinical team from those who agreed to participate in the SIEDS 
study. Information regarding the patient’s ethnicity and marital status was also collected by a 
clinical team member. The patients’ ethnicity was categorised by 1 = NZ European, 2 = 
Maori, 3 = Samoan, 4 = Cook Island, 5 = Tongan, 6 = Nieuean, 7 = Chinese, 8 = Indian and 
9 = other. The patient’s marital status was also categorised by 1 = married or living together 
1+years, 2 = separated, 3 = divorced, 4 = widowed and 5 = never married. 
 
Outcome measures 
The following measures were collected at pre-treatment, post treatment and 3-months after 
treatment was completed (3-month follow up);  
1. Patients weight in kilograms (kgs) is measured by therapists prior to each session 
to track specific changes in the individual’s weight during treatment.  
2. Patients height in metres (m) was measured prior to the start of treatment.  
From these measures (weight and height) each patient’s Body Mass Index (BMI) was 
calculated. The BMI takes into account height and weight of a patient and provides a score 
which determines whether they are in a healthy weight range based on their height. 
Individuals with a BMI range of 18.5 – 24.9 are considered to be in the healthy weight range 
based on the norm population. Whereas, according to the DSM-V, individuals with a BMI 
equal to or below 17 kg/m2 may be diagnosed with anorexia provided that other criteria’ of 
the eating disorder are met.  
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Self report measures 
Self-report measures were also used to collect information about the severity of patients 
anorexia nervosa and its associated features both prior to and after treatment; 
Eating disorder symptoms 
Eating Disorder Examination Questionnaire – 6th Edition (EDEQ-VI) (Fairburn & 
Beglin, 1994; Fairburn & Beglin, 2008).  
The EDEQ-VI was used to measure changes in patients eating disorder 
psychopathology before and after treatment. The self-reported EDEQ-VI is comprised 
of questions which measures the frequency of eating disorder behaviours which the 
patient has engaged in over the past 28 days to assess the severity of their eating 
disorder (Fairburn & Beglin, 2008). The EDE-Q also breaks down the questions into 
four subscales used to measure the severity of each patient’s eating disorder by taking 
into account their eating restraint behaviours, shape concern, eating concern and 
weight concerns (Fairburn & Beglin, 2008; Fairburn, Cooper & O’Connor, 2008). 
Finally, patients were also required to answer additional questions regarding their 
height, weight, number of missed menstrual periods and whether they were currently 
taking the contraceptive pill. The EDEQ has been shown to have good internal 
consistency ranging from α = 0.96-0.81 (Cronbach’s alpha) and re-test reliability (r = 
0.77-0.92) (Phillips, Jennings & Gregas, 2018; Rose, Vaewsorn, Rosselli-Navarra, 
Wilson & Weissman, 2013) 
 
Metacognitions 
Metacognitions questionnaire-30 (MCQ-30) (Wells & Cartwright-Hatton, 2004). 
Patients also completed the MCQ-30, a shortened self-reported questionnaire which 
was adapted from the Metacognitive Questionnaire (MCQ). This shortened MCQ-30 
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has been shown to have good internal consistency (Cronbach’s α = 0.72 - 0.93) (Wells 
& Cartwright-Hatton, 2004). The MCQ-30 is comprised of 30 questions used to 
assess the patient’s beliefs about their own cognitions (Wells & Cartwright-Hatton, 
2004). For each question patients were required to circle one of the four options 1 = 
Do Not Agree, 2 = Agree Slightly, 3 = Agree Moderately or 4 = Agree Very Much 
(Wells & Cartwright-Hatton, 2004). The MCQ-30 (Wells & Cartwright-Hatton, 2004) 
is divided up into five subscales which measures patients’; lack of cognitive 
confidence, cognitive self-consciousness, positive beliefs that worrying is beneficial, 
negative beliefs that thoughts are uncontrollable and dangerous and beliefs 
concerning the need to control thoughts. Therefore, the higher the scores in any of 
these five subscale areas is indicative of more maladaptive metacognitions (Hjemdal 
et al., 2017)   
 
Thought control 
Thought Control Questionnaire (TCQ) (Wells & Davies, 1994)  
The TCQ (Wells & Davies, 1994) is a self-reported psychometric measure comprised 
of 30 questions which is used to measure patients’ strategies for controlling 
unpleasant thoughts. For each question patients were required to choose one of four 
responses; 1 = Never, 2 = Sometimes, 3 = Often or 4 = Almost Always. Their 
responses are indicative of how often they utilise a different types of thought control 
strategies such as; distracting oneself from negative thoughts, social control, 
worrying, punishing oneself and reappraisal of the thought. These five categories of 
thought control (Distraction, social control, worry, punishment and re-appraisal) have 
been found to have good internal consistency ranging from α = 0.64-0.79 (Cronbach’s 
alpha) and re-test reliability r = 0.67- 0.83 (Wells & Davies, 1994). In regards to 
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adaptiveness of these thought control tools, strategies such as punishment and worry 
were proposed to lead to psychological distress (Wells & Davies, 1994).  
 
Depression 
Beck Depression Inventory Second Edition (BDI-II) (Beck, Steer & Brown, 1996). 
The BDI-II is used to measure whether an individual endorses symptoms of 
depression through a self-report form. Once the individual completes all 21 questions, 
the items are scored and totalled. The BDI-II has 4 categories for its total scores 
corresponding to depression symptom severity: 0-13 (minimal), 14-19 (mild); 20-28 
(moderate); 29-63 (severe). The BDI-II has an 0.93 alpha coefficient and re-test 
correlation (Beck et al., 1996) 
 
Worry 
Penn State Worry Questionnaire (PSWQ) (Meyer, Miller, Metzger & Borkovec, 1990) 
The PSWQ is a self-report questionnaire that is made up of 16 items used to assess 
worry. It has been demonstrated to have good internal consistency (α = 0.91- 0.95) 
and re-test reliability (Meyer et al., 1990).  
 
Rumination 
Rumination subscale of the Rumination-Reflection Questionnaire (RRQ) (Trapnell & 
Campbell 1999).  
The rumination subscale of the RRQ consists of 12 items used to measure the 
construct of rumination in individuals. Items such as “I often find myself revaluating 
something I’ve done” (Trapnell & Campbell, 1999, p. 293) are rated from (1) strongly 
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disagree, (2) disagree, (3) neutral, (4) agree or (5) strongly agree. The rumination 
subscale has good internal consistency (α = 0.90) (Trapnell & Campbell, 1999) 
 
Clinician measures  
The following global outcome measures were collected by clinicians at the SIEDS for each 
participant at both pre-treatment and post-treatment: 
1) Global rating of clinical state of eating disorder (Mcintosh et al., 2016) 
Clinicians used this to measure the number of eating disorder symptoms and whether 
the patient can be diagnosed with anorexia nervosa under the DSM-IV criteria. 
Clinicians utilise their clinical judgement to assess the extent of each patient’s eating 
disorder psychopathology. The following ratings (Mcintosh et al., 2016) were 
assigned to each patient; 1 = No significant features of eating disorder, 2 = A few 
features of eating disorder, 3 = Not full criteria for eating disorder but a number of 
features of eating disorder, 4 = Meets full criteria for an eating disorder. Patients 
who received a score of 4 (meets full criteria for an eating disorder) by the clinician 
were admitted into the trial provided that they did not meet any of the exclusionary 
criteria set out above.   
2) Global assessment of functioning-eating disorders (GAF-ED) (DSM-VI cited in 
Mcintosh et al., 2016) 
Clinicians used this to measure the severity of patients’ eating disorder by taking into 
account how their eating disorder impacts their current occupational, social and 
psychological well-being. The GAF-ED scoring system ranges from 1-100, which are 
broken up into ten separate categories. For example, patients who received a total 
score ranging from 1-10 were considered to be extremely impaired in their daily 
functioning, as they were in “persistent danger of severely hurting self or others . . . or 
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persistent inability to maintain minimal personal hygiene” (APA, 1994, p.32). 
Conversely, patients who received a total score between 91-100, are functionally 




Due to the small sample size of the present study (n = 12), a statistical approach 
which calculates and compares the inferential confidence intervals (CI) of two means (M) to 
ascertain statistical significant difference was performed. This method of statistical analysis 
is outlined in Tryon (2001).   
According to Tryon (2001), by calculating the inferential CI of two dependent means 
and comparing whether there is any overlap between the two CI’s, allows us to determine 
whether or not the means are statistically different. If the two dependent mean CI’s overlap, 
this indicates that the two means are not statistically different; whereas if there is no overlap 
present between the two CI’s we can accept that the two dependent means are statistically 
different from one another (Tryon, 2001).  
To determine whether there is a statistical difference between outcome measures 
before and after MCT intervention, the inferential CIs for the dependent means (pre-
treatment, post-treatment) of each outcome measure was calculated using the following 
formulae given in Tryon (2001):  
 





= 1	!%&                      (1) 
 
In equation (1) E is the value by which each CI needs to be reduced, by not only 
taking into account the standard errors of each mean (234+ , 234, ) but also factoring in the 
correlation (r) between pre-treatment and post-treatment measure. Once E has been 
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calculated, it is multiplied by the critical t value of the dataset at the 95% confidence level in 
order to determine whether the two means are statistically different at p < 0.05 (!%&). The 
confidence intervals for both means (pre-treatment and post-treatment outcome measure) 
were then calculated using equation (2). 
84 ± 1	!://	234 = 84 	± 1	!:// 	
(
√=
                               (2)  
 
          Once significant statistical difference is determined, the next step is to calculate 
whether or not the two CI’s of the mean are statistically equivalent. This is involves 
calculation by determining whether the lower limit of the CI of the lesser mean and the upper 
limit of the CI of the greater mean is less than delta (Tryon, 2001). If this is the case, then the 
two means are said to be statistically equivalent (Tryon, 2001).  Delta in the current study 
was set by as 1 standard deviation of the Pre-treatment mean.  
 If neither statistical significant difference nor statistical equivalence are found, then the 
results are said to be statistically indeterminant (Tryon, 2001), whereas, if the results are both 
statistically different and not statistically equivalent, then there is a statistical difference.  
Effect size. 
The effect size was calculated using the formulas provided by Cummings (2012) for 
Cohen’s d. In this formula the >?0@/  is the standard deviation of the pre treatment mean and 
>?ABC/  is the standard deviation of the post treatment mean. The symbol >DE is the standard 
deviation average and the FGHII  is the difference between pre treatment and post treatment 
means. Effect sizes were only calculated for measures with means that were statistically 
different and not statistically equivalent from pre-treatment to post-treatment.  Effect sizes for 




                  
 











In a modified Brinley plot analysis a scatter plot of each patient’s pre-treatment 
outcome score (x axis) is plotted against their corresponding post-treatment outcome score 
(x-axis) (Blampied, 2017). A diagonal 45º line is drawn on the scatter plot, this is known as 
the line where no change has occurred (Blampied, 2017).  Patients scores which fall on this 
line indicates that there was no change in their outcome measure scores from pre-treatment to 
post-treatment; scores that fall below the line, indicated a decrease in score, while scores 
above the line indicate an increase in scores (Blampied, 2017; Jacobson & Truax, 1991).  
Reliable Change. 
 To calculate how much change was needed in order for it to be a reliable change, the 
Reliable Change Index (RCI) was calculated. The RCI can be calculated by using equation 1-
3 (Blampied, 2017; Blampied, 2016; Jacobson & Truax, 1991). The standard error of the 
measure (21Q) is calculated in equation 1 where 2R is the standard deviation of a normal 
population and STT is reliability for a given measure. The 21Q  is then used to calculate the 
“standard error of the difference scores” (2UHII) (Blampied, 2017, p. 119) (see equation 2). 
To determine the upper and lower RCI at a significance level of p < .05, the 2UHII  is 
multiplied by 1.96 (see equation 3). Patients scores which fall within these RCI limits do not 
represent a reliable change from pre-treatment to post-treatment, as it is possible that due to 
measurement error similar changes may result (Blampied, 2017; Jacobson & Truax, 19991).  
21Q =	2RV1	 −	STT                     (1) 
 
2UHII = V2(2Z)/                           (2)   




[\](^.`&) = ±1.962UHII                  (3) 
 
 Once the RCI has been calculated, the upper and lower limits were plotted as dotted 
lines running on either side of the diagonal line which indicates no change (Blampied, 2017). 
Patient scores which fall beyond the RCI are considered to be a reliable change in the patients 
score (Blampied, 2017). Scores which lie beyond the RCI shows a change (either an increase 
if above the line, or decrease if below the line) from pre-treatment to post-treatment greater 
than what can be attributed to measurement error (Blampied, 2017; Jacobson & Truax, 1991)  
 In order to calculate the RCI, norms were obtained from previous studies which 
consisted of norms such as those similar to a normal population, or a normal sample with 
similar to patients in the current study (women) or normal sample who may be more at risk of 
developing an eating disorder such as college women (Quick & Bryd-Bredbenner, 2013).  
(EDE-Q: Quick & Byrd-Bredbenner, 2013; TCQ: Wells & Davies, 1994; MCQ-30: Wells, & 
Cartwright-Hatton, 2004; BMI: Stommel & Schoenborn, 2009; BDI-II: Whisman & 
Richardson, 2015; PSWQ: Gillis, Haaga & Ford, 1995; Meyer, Miller, Metzger & 
Borkovec,1990; RRQ: Trapnell & Campbell, 1999.  
In terms of the Global Rating of Clinical State of Eating Disorder measure the reliable 
change index was not able to be calculated. Furthermore, since all patients met the full 
criteria for an eating disorder at pre-treatment, the lack of variation in their pre-treatment 
scores for this measure resulted in a .00 SD (pre-treatment) score. Hence, it was decided that 
a description of the number of patients who showed reductions in their eating disorder 
symptoms would be provided. Furthermore, due to the lack of suitable norms for the Global 
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Clinically significant change. 
Jacobson and Truax (1991) requires two components for clinically significant change 
to be achieved. Firstly, individuals must achieve a reliable change, that is the change in their 
scores from pre-treatment to post-treatment is not a result of measurement error. Secondly, 
patients scores must fall beyond a certain cut off point (Jacobson & Truax, 1991).  
Some measures in the current study already had pre-existing clinical cut-off points as 
set by previous research (Blampied, 2017). For certain measures, (EDEQ-VI, MCQ-30, TCQ, 
RRQ, PSWQ) without set pre-existing clinical cut off points, the cut-off point was set at a 
change of 2SD from pre-treatment mean towards the ‘direction’ of improvement (Jacobson & 
Truax, 1991). For certain measures such as the EDE-Q restraint subscale measure, it was not 
possible to use a cut-off point that was 2SD from the pre-treatment mean, as this would result 
in a cut-off point that was below the lowest possible score for that measure. Therefore, the 
EDE-Q restraint subscale cut-off point was set at 1.5SD from the pre-treatment mean.  
The measures with pre-existing clinical cut-off points determined by previous 
literature are described below.  
The BMI measure’s cut-off point was set as follows: if patient’s score moved into the 
healthy weight range (BMI=18.5 to 24.9) as determined by the World Health Organisation 
(WHO, n.d.). In terms of the BDI-II measure, the cut-off point was defined by the guidelines 
set out in the BDI-II manual, where if patients experienced a reduction in the severity of their 
depression symptoms at post-treatment such that if they moved into the lowest severity index 
( ≤ 13 minimal depressive symptoms) they were defined as having met the clinical cut off 
point criteria (Beck, Steer & Brown, 1996). If patients were already in the lowest severity 
index (minimal depressive symptoms), they would only meet the cut-off point criteria if they 
showed no depressive symptoms at post-treatment as defined by the BDI-II manual (Beck, 
Steer & Brown, 1996).  
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A cut off point for the GAF-ED score of ≥ 71 was used as the sole criteria to 
determine clinically significant change. The GAF-ED measure defines patients whose scores 
are equal to or greater than 71 as having ‘transient’ or no symptoms with none or minor 








A total of 12 patients diagnosed with anorexia nervosa completed a minimum of 11 
MCT sessions with a clinician which was the minimum number of sessions required to be 
included for analysis in the present study. The number of sessions each patient in the present 
study received ranged from 11 to 42 sessions as the number of sessions received was 
dependent on their therapist’s clinical judgement of how much therapy was needed. The 
majority of patients who completed the study were NZ European (n = 10). The two patients 
who identified themselves as being from another ethnicity group but did not specify which. 
Patients in the present study ranged from 18 to 35 years of age (M = 22.17), with 18.33 years 
being the mean age of onset for their current eating disorder (see Table 1).  
Aside from being diagnosed with anorexia nervosa, nine out of the twelve patients in 
the study also had other co-occurring disorders such as major depressive disorder or an 
anxiety disorders. The number of patients who have other specific co-occurring disorders are 
outlined in Table 2. Furthermore, before starting the MCT trial nine patients sought treatment 
for their eating disorder (ED) and six patients had sought treatment for other problems as 















Number of patients with other co-occurring disorders 
 
Other Co-occurring Disorders N 
Post-traumatic Stress Disorder (PTSD) 1 
Subthreshold PTSD 1 
Generalised Anxiety Disorder (GAD) 5 
Obsessive-Compulsive Personality Disorder (OCPD) 2 
Major Depressive Disorder (MDD) 2 
Social Anxiety Disorder  2 
Borderline Personality Behaviours 1 











 N M SD 
Current Age 12 22.17 5.17 
 Clinical Demographics 
 N M SD 
Age of onset of any ED 11 16.45 2.95 
Age of onset of first ED 12 17.75 5.61 
Age of onset of current ED 12 18.33 5.55 





Number of patients who have sought other forms of treatment 
 
 Other Treatments 
 N 
Previous treatment for ED or weight problems 9 




      Due to missing data, only patients with both pre-treatment and post treatment outcome 
measures were analysed for statistical, clinical significance and reliable change. Therefore, 
some measures only had nine participants (PSWQ) while others had 12 participants (BMI) in 
the analysis.




 Group Data. 
Body Mass Index (BMI) 
 There was statistical difference in the average BMI of patients from pre-treatment to post-treatment, as the CI’s of both means do not 
overlap (see Table 4), with a medium effect size (d = 0.7826).  Furthermore, the two BMI means were not statistically equivalent. Hence, there 




Patients Body Mass Index (BMI) before and after MCT intervention 
 
Note. 




Eating disorder symptoms. 
 
Total symptoms (Eating Disorder Examination Questionnaire). 
 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 12 17.833 1.9289^ 0.5568  17.3966 -18.2694 
   
 
Post Treatment 12 19.460 2.2192 0.6406 0.755 18.9579-19.9621 2.5655 * ns -0.7826 
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 There was a decrease in the patients group mean EDEQ-VI global score after receiving MCT and the difference in EDEQ-VI mean 




Patients EDEQ-VI Global score before and after MCT intervention 
 
Note. 




Restraint, eating, shape and weight concern. 
 
There was a decrease in the mean scores of the restraint subscale, eating concern subscale, shape concern subscale, weight concern 
subscale measures from pre-treatment to post-treatment (see Table 6). Statistical difference was observed for each subscale measure from pre-
treatment to post-treatment. Furthermore these subscale scores were not statistically equivalent from pre-treatment to post-treatment. Large 
effect sizes were also observed across all subscales (d = 2.2158-2.7560).  
 
 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 10 3.819 1.4175^ .4483  3.1696-4.4684 
   
 
Post Treatment 10 .852 .6893 .2180 .340 0.5362-1.1678  3.9322 * ns 2.6621 






Patients EDEQ-VI subscale scores before and after MCT intervention 
Note. 







Global Rating of Clinical State of Eating Disorder. 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Restraint           
Pre Treatment 10 3.700 1.9669^ .6220  2.6920-4.7080 
   
 
Post Treatment 10 .520 .5007 .1583 .505 0.2635-0.7765  4.4445 * ns 2.2158  
           
Eating Concern           
Pre Treatment 10 3.700 1.1284^ .3568  3.2911-4.1089     
Post Treatment 10 .760 1.0013 .3166 .492 0.3972-1.1228 3.7117 * ns 2.7560 
           
Shape Concern           
Pre Treatment 10 4.175 1.3947^ .4410  3.5393-4.8107     
Post Treatment 10 1.287 1.0818 .3421 .207 0.7938-1.7802 4.0169 * ns 2.3139 
           
Weight Concern           
Pre Treatment 10 3.700 1.7544^ .5548  2.8058-4.5942     
Post Treatment 10 .840 .4881 .1543 .446 0.5913-1.0887 4.0029 * ns 2.2211 




Due to the type of numerical data collected for the Global Rating of Clinical State of Eating Disorder (ED) outcome measure, where 
patients were given a numerical rating of 1, 2, 3 or 4 depending on the severity of their eating disorder symptomology at pre-treatment and post-
treatment, the measure r which is used in Tryon’s formula to analyse whether a statistical difference was observed could not be determined.  
However, the descriptive statistics of the raw data (Table 7), suggest that there was a decrease in the mean of the Global Rating of Clinical State 
of ED from pre-treatment to post-treatment. 
Table 7 
 
Patients Global Rating of Clinical State of ED score before and after MCT 
 
Time N M SD Range 
Pre Treatment 11 4.00 .00 0 
Post Treatment 11 2.55 1.128 3 
 
 
Global functioning (Global Assessment of Functioning – Eating Disorders (GAF-ED)). 
 
The GAF-ED mean scores increased from pre-treatment to post-treatment, and were both statistically different and not statistically 











Patients GAF-ED score before and after MCT intervention 
 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 11 46.45 7.776^ 2.345  42.8403-50.0597 
   
 
Post Treatment 11 64.45 13.859  4.179  0.135 58.0173-70.8827 28.0424 * ns -1.6019 
Note. 




Metacognitions (Metacognitions Questionnaire-30 (MCQ-30)). 
Total Metacognitions. 
 The MCQ-30 total mean scores decreased from pre-treatment to post-treatment and were statistically different and not statistically 
equivalent from pre-treatment to post-treatment, (Table 9), with a large effect size (d = 1.8164).   
Table 9 
 
Patients MCQ-30 Total Score before and after MCT intervention 
Note. 
r = Pearson’s Correlation, ^ = delta interval, Rg = maximum mean difference, * = statistically significant at .05, ns = not statistically significant 
at .05 
 
Positive and negative metacognitions. 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 11 81.09 17.941^  5.410  72.6358-89.54428 
   
 
Post Treatment 11 52.27 13.477 4.063 0.037 45.9207-58.6193 43.6235 * ns 1.8164 




For each of the following MCQ-30 subscales (positive beliefs, uncontrollability and danger, need to control thoughts and cognitive self-
consciousness) there was a decrease in group mean scores after patients received MCT intervention (Table 10). For each of these subscales the 
scores were statistically different and not statistically equivalent from pre-treatment to post-treatment.  
For the cognitive confidence subscale, the scores were not statistically different and not statistically equivalent between pre-treatment to 
post-treatment, hence the results for this subscale was statistically indeterminate and not conclusions can be drawn.  These results indicates that 
apart from the cognitive confidence subscale, MCT intervention was helpful in reducing other maladaptive metacognitions in patients, with 
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Patients MCQ-30 subscale scores before and after MCT intervention 
 
Note. 
r = Pearson’s Correlation, ^ = delta interval, Rg = maximum mean difference * = statistically significant at .05, ns = not statistically significant at 
.05 
 
Thought Control (TCQ). 
 
TCQ Total 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Positive Beliefs            
Pre Treatment 11 16.55 4.367^ 1.317  14.5039-18.5961 
   
 
Post Treatment 11 9.55 2.945 0.888  0.068 8.1704-10.9296 10.4257 * ns 1.8794      
 
    
 
Uncontrollability and Danger            
Pre Treatment 11 18.36 5.104^ 1.539  15.5630-21.1570     
Post Treatment 11 9.82 2.401 0.724 -0.231 8.5042-11.1358 12.6528 * ns 2.1412 
           
Cognitive Confidence           
Pre Treatment 11 15.00 4.712^ 1.421  13.1270-16.8730     
Post Treatment 11 11.18 5.997 1.808 0.319  8.7969-13.5631 8.0761 ns ns  
           
Need to Control Thoughts           
Pre Treatment 11 15.18 5.456^ 1.645  12.4470-17.9130     
Post Treatment 11 9.00 2.828 0.853 -.013 7.5828-10.4172 10.3302 * ns 1.4222 
           
Cognitive Self-Conciousness           
Pre Treatment 11 16.00 2.933^ 0.884  14.6706-17.3294     
Post Treatment 11 12.73 2.370 0.715 0.101 11.6547-13.8053 5.6747 * ns 1.2264 




 The TCQ total mean scores was not statistically different between pre-treatment to post-treatment and were statistically equivalent (Table 




Patients TCQ Total score before and after MCT intervention 
 
Note. 




Thought Control Questionnaire subscales (worry and punishment). 
 
 The TCQ worry subscale mean scores decreased from pre-treatment to post treatment and the scores were both statistically different and 
were not statistically equivalent, with a large effect size (d = 1.1449). However, the TCQ punishment subscale mean scores from pre-treatment 
to post- treatment were both statistically different and statistically equivalent (Table 12). This means that no conclusions can be drawn about the 




Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 11 62.64 10.072^ 3.037  59.0667-66.2133 
   
 
Post Treatment 11 63.91 6.410^  1.933 0.517 61.6356-66.1844  7.1177 ns * -0.1504 
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Patients TCQ subscale scores before and after MCT intervention 
 
Note. 

















Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
TCQ Worry            
Pre Treatment 11 13.55 4.228^ 1.275  12.0203-15.0797 
   
 
Post Treatment 11 9.64 2.335  0.704  0.549 8.7953-10.4847  6.2844 * ns 1.1449      
 
    
 
TCQ Punishment           
Pre Treatment 11 10.64 3.443^ 1.038  9.7931-11.4869     
Post Treatment 11 9.00 2.569 0.775 0.769 8.3677-9.6323 3.1192 * *  
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 There was a reduction in the group mean scores on the BDI-II from pre-treatment to post treatment, the scores were statistically different 




Patients BDI-II score before and after MCT intervention 
 
Note. 






 There was a decrease in the RRQ-rumination mean score from pre-treatment to post-treatment and the scores were both statistically 







Patients RRQ rumination subscale score before and after MCT intervention 
 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 9 26.67 14.318^ 4.773  19.2184-34.1216  
   
 
Post Treatment 9 7.44 7.535 2.512 .199 3.5183 -11.3617  30.6033 * ns 1.6808 










 There was a decrease in the PSWQ mean score from pre-treatment to post-treatment and the scores were both statistically different and 
statistically not equivalent (see Table 15), with a large effect size (d = 1.8715).   
Table 15 
 
Patients PSWQ score before and after MCT intervention 
 
Note. 
r = Pearson’s Correlation, ^ = delta interval, Rg = maximum mean difference, * = statistically significant at .05, ns = not statistically significant 
at .05 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 11 50.82 6.809^ 2.053  48.1847-53.4552  
   
 
Post Treatment 11 38.18 6.047 1.823 0.341 35.8400-40.5200 17.6152 * ns 1.9630 
Time N M SD SEM r 95% CI Rg Different Equivalent Cohen’s d 
Pre Treatment 9 64.11 11.483^ 3.828  58.7305-69.4895 
   
 
Post Treatment 9 43.56 10.454 3.485 0.260 38.6625-48.4575  30.827 * ns 1.8715 
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Summary of group results 
 
It was hypothesised that patients receiving MCT modified for anorexia nervosa would 
show a significant increase in their body weight and a decrease in their eating disorder 
symptoms.  
Based on the overall group mean scores, patients mean BMI scores showed a 
statistical increase after receiving MCT for their anorexia nervosa, with a medium effect size 
of d = 0.7826. This result provided support for the hypothesis that patients receiving modified 
MCT for their anorexia nervosa would experience weight gain.  
 Patients mean EDEQ-VI global score and associated subscales (restraint, eating 
concern, shape concern, weight concern) scores also displayed a statistical decrease from pre-
treatment to post-treatment, indicating a reduction in the groups eating disorder 
symptomology. Further, large effect sizes were observed across all EDEQ-VI global and 
subscale scores, ranging from d = 2.2158 to d = 2.7560. 
 This apparent reduction in patients’ eating disorder symptoms was further supported by 
the increase in their GAF-ED mean scores, which was statistically different from pre-
treatment to post-treatment. This suggests improvements in eating disorder severity after 
receiving MCT intervention. This improvement in patients GAF-ED scores was also 
associated with a large effect size of d = 1.6019.  
 There was a decrease in the patients mean Global Rating of Clinical State of ED score 
from pre-treatment to post treatment, indicating a reduction in the severity of patients eating 
disorder symptoms, which had a large effect size (d = 1.8179). However due to the nature of 
the data set, it was not possible to analyse if the pre-treatment and post-treatment scores were 
statistically different.  
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 It was also hypothesised that modified MCT would reduce patients maladaptive 
metacognitions and thought control strategies. Statistical analyses showed a decrease in the 
group’s mean metacognitions scores (MCQ-30 total score) from pre-treatment to post-
treatment, which was statistically different and has a large effect size of d = 1.8164. This 
indicates an improvement in groups maladaptive metacognitions after undergoing MCT 
intervention. Upon closer analysis of the MCQ-30 subscales measure, the results showed that 
after receiving MCT intervention there was a decrease in the groups following MCQ-30 
subscale scores, which were all statistically different with large effect sizes; Positive Beliefs 
(d = 1.8794), Uncontrollability and Danger (d = 2.1412), Need to Control Thoughts (d = 
1.4222) and Cognitive Self-consciousness (d = 1.2264). However, for the MCQ-30 subscale 
of cognitive confidence, the results were statistically indeterminate, thus no conclusions can 
be drawn about this subscale.  
 The results showed that there was no difference in patients overall use of thought 
control strategies (TCQ total) when comparing pre-treatment to post treatment group means. 
Which suggests that there was no change in their use of thought control strategies after MCT 
intervention based on the total TCQ score. Analysis of the groups TCQ punishment subscale 
scores from pre-treatment to post-treatment revealed statistically indeterminate results, thus 
no significant conclusions can be drawn for subscale. However, there was a decrease in the  
TCQ worry subscale mean scores from pre-treatment to post treatment, which was 
statistically different, with a large effect size of d = 1.1449. This indicates that patients 
reduced their use of worry as a thought control strategy after receiving MCT.  
 It was also predicted that modified MCT for anorexia nervosa would result in a 
decrease of rumination, depressive and worry symptoms. The results showed that there was a 
reduction in the patients BDI-II scores, level of rumination (RRQ-rumination subscale), and 
worry from pre-treatment to post-treatment. All three measures had mean scores that were 
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statistically different from pre-treatment to post-treatment. Further, all these changes had a 




Reliable Change Index and Modified Brinley Plots. 
 
The reliable change index was calculated and displayed on Brinley plots for the 
following measures in the study below. It should be noted that for the Brinley plots, the 
dotted lines running on both sides of the diagonal line which indicates no change are the 
reliable change index boundaries (lower and upper), (Blampied, 2017). 
 
Body Mass Index (BMI). 
 
The majority of patients (10 out of 12) showed a reliable improvements (i.e. an 
increase) in their BMI scores from pre-treatment to post-treatment. However, one patient had 











Body Mass Index (BMI)
Pre Treatment

















Note.. Brinley plot of patients pre and post-treatment 
BMI. RCI (+/- 0.08). 
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Eating Disorder Symptoms. 
 A total of 10 out of the 12 patients in the study completed the EDEQ-VI 
questionnaire. Nine of these 10 patients had a positive reliable change (a decrease in score) in 
their EDE-Q global scores from pre-treatment to post-treatment (Figure 3). Further analysis 
of the EDE-Q subscales revealed that eight out of the 10 patients had reliable improvements 
(decrease in score) in their EDE-Q restraint subscale scores after intervention (see Figure 4). 
Moreover, nine out of 10 patients also had reliable improvements (decrease in score) in their 
EDE-Q eating concern subscale scores (see Figure 5). Additionally, eight patients had a 
positive reliable reduction in their EDE-Q shape concern subscale scores from pre-treatment 
to post-treatment (Figure 6). Further, on the EDE-Q weight concern subscale measure seven 
out of the 10 patients had reliable improvement (decrease in score) after undergoing MCT 






























Note. Brinley plot of patients pre and post-treatment 
EDEQ-VI Global. RCI (+/- 0.80).  
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Figure 6                                                                     



























EDE-Q Eating Concern subscale
Pre Treatment
















EDE-Q Shape Concern subscale
 
Pre Treatment
















EDE-Q Weight Concern subscale
Pre Treatment
















Note. Brinley plot of patients pre and post-treatment 
EDEQ-VI restraint subscale. RCI (+/- 1.59).  
Note.  Brinley plot of patients pre and post-treatment 
EDEQ-VI eating concern subscale. RCI (+/- 1.35).  
Note. Brinley plot of patients pre and post-treatment 
EDEQ-VI shape concern subscale. RCI (+/- 1.35). 
Note. Brinley plot of patients pre and post-treatment 
EDEQ-VI weight concern subscale. RCI (+/- 1.72). 
Note. Two individuals had exactly the same pre-treatment 
and post-treatment scores, which meant their individual 
data points overlapped, hence for the purposes of making 
all the individual data points visible, the post-treatment 
score for one of the two individual identical data points 
was slightly altered only for this Figure.  




In terms of the MCQ-30 outcome measure, 11 out of the 12 patients completed the 
questionnaire at both pre-treatment and post-treatment. Nine patients showed reliable 
improvements (decrease in score) in their MCQ-30 Total score after receiving treatment 
(Figure 8). Closer analysis of the MCQ-30 subscales also revealed that after MCT 
intervention, nine patients had reliable improvements (decrease in score) in their positive 
beliefs subscale scores (see Figure 9). A total of seven patients showed a positive reliable 
change (decrease in score) in their Uncontrollability and Danger subscale scores after MCT 
(see Figure 10). Six patients also had reliable improvements (decrease in score) in their 
cognitive confidence subscale scores after undergoing MCT, while three patients showed a 
reliable deterioration (increase in score) in this measure after MCT (Figure 11). Reliable 
improvements (decrease in score) in the MCQ-30 Need to Control thoughts subscale scores 
from pre-treatment to post-treatment were also observed in seven patients (see Figure 12). 
Whereas, only five patients displayed reliable improvements (decrease in score) in their 
Cognitive Self-Consciousness subscale scores after receiving MCT (see Figure 13).  























MCQ-30 Postive Beliefs subscale
Pre Treatment



















Note.. Brinley plot of patients pre and post-treatment MCQ-
30 Total score. RCI (+/- 9.76). 
Note.  Brinley plot of patients pre and post-treatment 
MCQ-30 Positive Beliefs subscale. RCI (+/- 2.72).  
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 Eleven patients completed the TCQ pre-treatment and post treatment questionnaire. 
Analysis of the TCQ Total scores revealed that three out of the 11 patients showed reliable 
deterioration (increase in score) in their scores for this measure after receiving intervention 
and only two out of the 11 patients showed reliable improvements (decrease in score) in their 
TCQ total scores at post-treatment (as seen in Figure 14). Further analysis of the TCQ 
MCQ-30 Negative Beliefs about 
Uncontrollability and Danger subscale
Pre Treatment



















MCQ-30 Cognitive Confidence subscale
Pre Treatment



















MCQ-30 Need to Control Thoughts subscale
Pre Treatment



















MCQ-30 Cognitive Self-Consciousness subscale
Pre Treatment



















Note.  Brinley plot of patients pre and post-treatment 
MCQ-30 Cognitive Confidence subscale. RCI (+/- 2.96). 
Note. Brinley plot of patients pre and post-treatment MCQ-30 
Cognitive Self-Consciousness subscale. RCI (+/- 3.67). 
Note. Brinley plot of patients pre and post-treatment MCQ-
30 Negative Beliefs about Uncontrollability and Danger 
subscale. RCI (+/- 3.33). 
Note. Brinley plot of patients pre and post-treatment MCQ-
30 Need to Control Thoughts subscale. RCI (+/- 3.86). 
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subscales showed that seven out of 11 patients showed reliable improvements (decrease in 
score) in their TCQ Worry subscale scores after MCT (as seen in Figure 15). Whereas, in the 
TCQ punishment subscale only a single patient showed reliable improvement (decrease in 








































































Note.. Scatter plot of patients pre and post-treatment TCQ 
total score. RCI (+/- 7.10). 
Note. Scatter plot of patients pre and post-treatment TCQ 
worry subscale. RCI (+/- 3.80). 
Note.  Scatter plot of patients pre and post-treatment TCQ 
punishment subscale. RCI (+/- 4.43). 





 Nine out of the 12 patients in the study completed the BDI-II measure at both pre-
treatment and post-treatment. A total of seven out of these nine patients showed reliable 
improvements (decrease in score) in their BDI-II Total scores from pre-treatment to post-











 Eleven out of the 12 patients completed the RRQ-rumination subscale questionnaire. 
All 11 patients showed reliable improvements (decrease in score) on the RRQ-rumination 

























Note.  Scatter plot of patients pre and post-treatment BDI-II 
Total score. RCI (+/-7.03) 
 











In terms of the PSWQ, nine out of the 12 patients completed this questionnaire at pre-
treatment and post-treatment. Eight of these nine patients had reliable improvements 







RRQ - Rumination subscale
Pre-Treatment





































Note.  Scatter plot of patients pre and post-treatment RRQ-
Rumination subscale.  RCI (+/-0.61). 
Note. Scatter plot of patients pre and post-treatment PSWQ 
Total score. RCI (+/-7.82 ). 
 






Clinically significant changes. 
 
The following tables below display the individuals who have achieved clinically significant changes across the different measures. As 
previously stated, clinically significant change is only achieved if a patient shows a) a reliable change in scores and b) their post treatment scores 
meets the cut off criteria (Jacobson & Truax, 1991). Certain measures had a pre-existing clinical cut off criteria as defined by previous research. 
Other measures had a cut off criteria of improvement of scores of at least two standard deviations (based on pre-treatment SD) from the pre-
treatment mean.  
 
BMI. 
 Results showed that four out of 12 patients had experienced clinically significant changes of improvements in their BMI scores, as their 
post-treatment BMI had increased to a healthy weight range and there was also a reliable change (improvement) in their scores (Table 16). One 
patient had a clinically significant change of deterioration, as they had a reliable deterioration in their BMI scores and their post-treatment BMI 











Changes in individuals Body Mass Index from pre-treatment to post-treatment.  
ID Pre-treatment Post-treatment Reliable Change  
Cut off (moved into or away 




Patient 1 19.8 18.4 Yes (–) Yes × 
Patient 2 16.5 16.5 No No  
Patient 3 14.7 16.8 Yes (+) No  
Patient 4 17.7 20.6 Yes (+) Yes * 
Patient 5 19.3 21.2 Yes (+) No  
Patient 6 21.1 24 Yes (+) No  
Patient 7 20.1 21.4 Yes (+) No  
Patient 8 17.1 18 Yes (+) No  
Patient 9 16.3 17.7 Yes (+) No  
Patient 10 15.7 19.4 Yes (+) Yes * 
Patient 11 18 18.6 Yes (+) Yes * 
Patient 12 17.7 21 Yes (+) Yes * 
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 
+ = reliable change (improvement), – = reliable change (deterioration) 
 
Eating Disorder Symptoms. 
 As previously stated, out of the 12 patients in the present study, only 10 completed the EDE-Q questionnaire at both pre-treatment and 
post-treatment. Hence, the EDE-Q results of these 10 patients will be analysed below.   
 






After receiving MCT intervention, seven out of the 10 patients showed clinically significant changes of improvements in their EDE-Q 
global scores, as all seven patients showed reliable improvements in their EDE-Q global scores and met the cut off criteria at post-treatment (see 
Table 17).  
Table 17 
Changes in individuals EDEQ-VI Total from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off criteria (<0.984) Clinically Significant 
Patient 1 5.1 2.5 Yes (+) No  
Patient 2 4.1 0.9 Yes (+) Yes * 
Patient 4 2.2 0 Yes (+) Yes * 
Patient 5 4.9 0.1 Yes (+) Yes * 
Patient 6 4.8 0.6 Yes (+) Yes * 
Patient 7 4.9 0.8 Yes (+) Yes * 
Patient 9 1.5 0.8 No Yes  
Patient 10 1.9 0.8 Yes (+) Yes * 
Patient 11 3.8 0.9 Yes (+) Yes * 
Patient 12 5.1 1.2 Yes (+) No  
Note. * = Clinically Significant Change (improvement), × = Clinically significant change (deterioration) 











 Upon analysis it was found that predetermined cut off criteria (2sd from the pre-treatment mean) for the EDE-Q restraint subscale was 
unachievable, as it fell below the lowest possible score for this measure (< -0.2338). Hence, it was necessary to adjust the cut off point for this 
measure to 1.5sd from the pre-treatment mean which makes the new cut off point as (<0.74965). Five patients had both reliable improvement in 
their EDE-Q restraint subscale scores and had a post-treatment score below the cut off point (see Table 18). Hence, these five patients had 
clinically significant change of improvements in their EDE-Q restraint scores after receiving MCT intervention.  
Table 18 













Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 
+ = reliable change (improvement), – = reliable change (deterioration) 
 
ID Pre-Treatment Post-Treatment Reliable Change  Cut off point ( <0.74965) Clinically significant 
Patient 1 5.4 1.4 Yes (+) No  
Patient 2 3.2 0.2 Yes (+) Yes * 
Patient 4 2.6 0 Yes (+) Yes * 
Patient 5 4.8 0 Yes (+) Yes * 
Patient 6 5.2 0.4 Yes (+) Yes * 
Patient 7 4.2 0.4 Yes (+) Yes * 
Patient 9 0.2 0.4 No Yes  
Patient 10 0.8 0.2 No Yes  
Patient 11 4.6 1.2 Yes (+) No  
Patient 12 6 1 Yes (+) No  






 Eight out of the 10 patients showed clinically significant changes of improvements in their EDE-Q eating concern scores after receiving 
MCT, with reliable improvements and scores that were below the cut off threshold at post-treatment (see Table 19).  
Table 19 
 Changes in individuals EDEQ-VI Eating Concern subscale from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off point (<1.4432) Clinically Significant 
Patient 1 5 3.4 Yes (+) No  
Patient 2 4.8 1 Yes (+) Yes * 
Patient 4 2.6 0 Yes (+) Yes * 
Patient 5 4 0 Yes (+) Yes * 
Patient 6 4.8 0.4 Yes (+) Yes * 
Patient 7 3.2 0 Yes (+) Yes * 
Patient 9 1.6 0.6 No Yes  
Patient 10 3.4 0.6 Yes (+) Yes * 
Patient 11 3 0.6 Yes (+) Yes * 
Patient 12 4.6 1 Yes (+) Yes * 
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 














Shape Concern.  
 Four out of 10 patients had reliable improvements in their EDE-Q shape concern scores and had a post-treatment score that was below 
the cut off point (see Table 20), suggesting clinically significant change of improvements in their EDE-Q shape concern scores.  
 
Table 20 
Changes in individuals EDEQ-VI Shape Concern subscale from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change Cut off point (<1.3856) Clinically Significant 
Patient 1 5.1 3.9 No No  
Patient 2 4.4 1.6 Yes (+) No  
Patient 4 2.3 0.1 Yes (+) Yes * 
Patient 5 5 0 Yes (+) Yes * 
Patient 6 5.1 0.9 Yes (+) Yes * 
Patient 7 6 1.4 Yes (+) No  
Patient 9 3 1.5 Yes (+) No  
Patient 10 1.8 1.5 No No  
Patient 11 4.1 0.6 Yes (+) Yes * 
Patient 12 5 1.4 Yes (+) No  
Note. * = Clinically Significant Change (improvement), × = Clinically significant change (deterioration) 













 No patients achieved clinically significant changes on the EDE-Q weight concern subscale scores as no patient met the required two-fold 
criterion of having both a reliable change in scores and meeting the cut off point criteria (see Table 21).  
Table 21 
Changes in individuals EDEQ-VI Weight Concern subscale from pre-treatment to post-treatment.  
ID 
Pre-
Treatment Post-Treatment Reliable Change  Cut off point (<0.1912) Clinically Significant 
Patient 1 4.8 1.4 Yes (+) No  
Patient 2 4 0.6 Yes (+) No  
Patient 4 1.2 0 No  Yes  
Patient 5 5.6 0.2 Yes (+) No  
Patient 6 4.2 0.8 Yes (+) No  
Patient 7 6 1.4 Yes (+) No  
Patient 9 1.4 0.8 No No  
Patient 10 1.6 0.8 No No  
Patient 11 3.4 1 Yes (+) No  
Patient 12 4.8 1.4 Yes (+) No  
Note. * = Clinically Significant change (improvement), × = Clinically significant change (deterioration) 













Global Rating of Clinical State of Eating Disorder. 
Out of the 11 patients who completed the Global Rating of Clinical State of Eating Disorder measure at both pre-treatment and post-
treatment, at post-treatment three patients had no significant eating disorder symptoms, one patient only had a few eating disorder symptoms 
present, five patients had some eating disorder symptoms present but no longer met the criteria for an eating disorder, and two patients remained 
unchanged and still had an eating disorder following intervention (see Table 22).   
Table 22 
Changes in individuals Global Rating of Clinical State of Eating Disorder from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment 
Patient 1 4 3 
Patient 2 4 3 
Patient 4 4 1 
Patient 5 4 1 
Patient 6 4 1 
Patient 7 4 3 
Patient 8 4 4 
Patient 9 4 3 
Patient 10 4 3 
Patient 11 4 2 











Global Assessment of Functioning-Eating Disorders (GAF-ED). 
In regards to the GAF-ED measure, only 11 out of 12 patients in this study received GAF-ED scores at both pre-treatment and post-
treatment, hence the results of these 11 patients will be analysed below.  
Based on the cut off of GAF-ED post-treatment score ≥ 71, it was found that three patients had experienced improvements in their eating 
disorder symptoms and daily functioning after receiving MCT (see Table 23).  
Table 23 





Treatment Cut off point (≥71) 
RH01 Patient 1 50 60  
RH02 Patient 2 40 55  
RH06 Patient 4 40 80 * 
RH09 Patient 5 40 85 * 
RH11 Patient 6 51 80 * 
LJ01 Patient 7 52 62  
LJ03 Patient 8 40 40  
LJ05 Patient 9 40 49  
JV01 Patient 10 41 68  
JV02 Patient 11 61 70  
JV03 Patient 12 56 60  
Note. * = significant change (improvement), × = significant change (deterioration) 
 
 






 As previously mentioned, 11 out of 12 patients in the study completed the MCQ-30 at both pre-treatment and post-treatment, therefore 
analysis of clinical significant change for the MCQ-30 measure will focus on these 11 patients.  
Metacognitions total. 
 Three out of the 11 patients achieved both reliable improvement and had a post-treatment score below the cut off point for the MCQ-30 
total score. Hence, after receiving intervention, three patients had clinically significant change of improvements in their unhelpful 
metacognitions according the MCQ-30 total measure (see Table 24).  
Table 24 
Changes in individuals MCQ-30 Total from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off criteria (<45.208) Clinically Significant 
Patient 1 84 64 Yes (+) No  
Patient 2 78 48 Yes (+) No  
Patient 3 94 80 Yes (+) No  
Patient 4 46 37 No Yes  
Patient 5 102 36 Yes (+) Yes * 
Patient 7 97 49 Yes (+) No  
Patient 8 77 55 Yes (+) No  
Patient 9 64 52 Yes (+) No  
Patient 10 105 42 Yes (+) Yes * 
Patient 11 79 45 Yes (+) Yes * 
Patient 12 66 67 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 
+ = reliable change (improvement), – = reliable change (deterioration) 







A total of four out of 11 patients had clinically significant improvements in the MCQ-30 Positive Beliefs subscale scores after receiving 
MCT, with both reliable improvements in their MCQ-30 Positive beliefs scores and a post-treatment score below the cut off point (see Table 25).  
Table 25 
Changes in individuals MCQ-30 Positive Beliefs subscale  from pre-treatment to post-treatment.  
ID 
Pre-
Treatment Post-Treatment Reliable Change  Cut off point (<7.816) Clinically Significant 
Patient 1 15 11 Yes (+) No  
Patient 2 11 6 Yes (+) Yes * 
Patient 3 22 13 Yes (+) No  
Patient 4 12 6 Yes (+) Yes * 
Patient 5 23 6 Yes (+) Yes * 
Patient 7 12 10 No No  
Patient 8 16 11 Yes (+) No  
Patient 9 13 12 No No  
Patient 10 21 6 Yes (+) Yes * 
Patient 11 20 11 Yes (+) No  
Patient 12 17 13 Yes (+) No  
Note. * = Clinically significant change, × = Clinically significant change (deterioration) 











Uncontrollability and Danger. 
Two patients out of the 11 patients who completed the MCQ-30 uncontrollability and danger subscale measure had both reliable 
improvement in their scores and were below the cut off at post-treatment. Hence, only these two patients showed clinically significant changes 
(reduction) in their negative beliefs of uncontrollability and danger after receiving intervention (see Table 26).  
Table 26 
Changes in individuals MCQ-30 Uncontrollability and Danger subscale from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off point (<8.152) Clinically Significant 
Patient 1 18 8 Yes (+) Yes * 
Patient 2 22 10 Yes (+) No  
Patient 3 23 12 Yes (+) No  
Patient 4 9 7 No Yes  
Patient 5 22 9 Yes (+) No  
Patient 7 21 9 Yes (+) No  
Patient 8 16 13 No No  
Patient 9 13 12 No No  
Patient 10 23 9 Yes (+) No  
Patient 11 23 6 Yes (+) Yes * 
Patient 12 12 13 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 












No patients achieved clinically significant changes in their MCQ-30 Cognitive Confidence scores after receiving MCT as no patients had 
both a reliable improvement and a post-treatment score which reached the cut-off criteria (Table 27). This is unsurprising as the group score for 
cognitive confidence was statistically indeterminate.   
Table 27 
Changes in individuals MCQ-30 Cognitive Confidence subscale from pre-treatment to post-treatment.  
ID 
Pre-
Treatment Post-Treatment Reliable Change Cut off point (<5.576) Clinically Significant 
Patient 1 16 19 Yes (–) No  
Patient 2 14 9 Yes (+) No  
Patient 3 19 24 Yes (–) No  
Patient 4 9 7 No No  
Patient 5 20 8 Yes (+) No  
Patient 7 23 10 Yes (+) No  
Patient 8 13 9 Yes (+) No  
Patient 9 11 7 Yes (+) No  
Patient 10 18 6 Yes (+) No  
Patient 11 8 7 No No  
Patient 12 14 17 Yes (–) No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 










Need to Control Thoughts. 
 No patients experienced clinically significant changes in their MCQ-30 Need to control thoughts subscale scores after receiving 
intervention as no patient had both a reliable improvement and a post-treatment score which reached the cut-off criteria (see Table 28).  
Table 28 
Changes in individuals MCQ-30 Need to Control thoughts subscale from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off point (<4.268) Clinically Significant 
Patient 1 18 10 Yes (+) No  
Patient 2 15 10 Yes (+) No  
Patient 3 17 16 No No  
Patient 4 6 6 No No  
Patient 5 20 6 Yes (+) No  
Patient 7 23 8 Yes (+) No  
Patient 8 14 8 Yes (+) No  
Patient 9 10 9 No No  
Patient 10 22 7 Yes (+) No  
Patient 11 13 8 Yes (+) No  
Patient 12 9 11 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 













Only one out of 11 patients showed clinically significant changes (reduction) on the cognitive self-consciousness MCQ-30 subscale after 
MCT, with reliable improvements in their scores and a post-treatment score below the cut off point (see Table 29).  
Table 29 
Changes in individuals MCQ-30 Cognitive Self-Consciousness subscale from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off point (<10.134) 
Clinically 
Significant 
Patient 1 17 16 No No  
Patient 2 16 13 No No  
Patient 3 13 15 No No  
Patient 4 10 11 No No  
Patient 5 17 7 Yes (+) Yes * 
Patient 7 18 12 Yes (+) No  
Patient 8 18 14 Yes (+) No  
Patient 9 17 12 Yes (+) No  
Patient 10 21 14 Yes (+) No  
Patient 11 15 13 No No  
Patient 12 14 13 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 














The following results were of those who completed the Thought Control Questionnaire at pre-treatment and post-treatment. A total of 11 
out of 12 patients completed the Thought Control Questionnaire in this study.  
Analysis showed that despite receiving intervention, no patients managed to achieve clinically significant changes in their TCQ total 
scores (see Table 30).  
Table 30 
Changes in individuals TCQ Total from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change Cut off point (<42.496) Clinically Significant 
Patient 2 63 71 Yes (–) No  
Patient 3 55 61 No No  
Patient 4 57 55 No No  
Patient 5 57 67 Yes (–) No  
Patient 6 72 62 Yes (+) No  
Patient 7 77 67 Yes (+) No  
Patient 8 68 68 No No  
Patient 9 54 51 No No  
Patient 10 76 69 No No  
Patient 11 45 62 Yes (–) No  
Patient 12 65 70 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 
+ = reliable change (improvement), – = reliable change (deterioration) 
 





TCQ Worry subscale. 
 No patients had clinically significant changes in the TCQ Worry subscale measure after intervention (Table 31).  
Table 31 
 Changes in individuals TCQ Worry subscale from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change Cut off point (<5.094) Clinically Significant 
Patient 2 22 11 Yes (+) No  
Patient 3 17 12 Yes (+) No  
Patient 4 10 6 Yes (+) No  
Patient 5 11 6 Yes (+) No  
Patient 6 17 10 Yes (+) No  
Patient 7 17 11 Yes (+) No  
Patient 8 12 12 No No  
Patient 9 11 7 Yes (+) No  
Patient 10 14 12 No No  
Patient 11 8 9 No No  
Patient 12 10 10 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 











TCQ Punishment subscale. 
None of the patients in the study had shown clinically significant changes on the TCQ Punishment subscale after MCT (Table 32).  
Table 32 
Changes in individuals TCQ Punishment subscale scores from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change Cut off point (<3.754) 
Clinically 
Significant 
Patient 2 11 8 No No  
Patient 3 11 10 No No  
Patient 4 6 6 No No  
Patient 5 8 7 No No  
Patient 6 11 11 No No  
Patient 7 19 15 No No  
Patient 8 12 9 No No  
Patient 9 7 8 No No  
Patient 10 11 9 No No  
Patient 11 12 6 Yes (+) No  
Patient 12 9 10 No No  
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 
+ = reliable change (improvement), – = reliable change (deterioration) 
 
Depression. 
As previously stated, patients were considered to have met the clinical cut-off point criteria if they moved into a minimal range of 
depression symptom severity of  ≤ 13 at post-treatment. However, some patients were already in the minimal range of severity for depression, 





hence, an additional cut off point was added, where patients in the minimal range had to achieve a score of 0 (showing no depressive symptoms 
on the BDI-II measure).  
A total of five out of nine patients who completed the BDI-II had a clinically significant change of reduction in their BDI-II Total score 
after MCT, indicating an improvement in their depressive symptoms. These five patients had met the two-fold criteria for clinically significant 
change by showing reliable improvements in their BDI-II scores and meeting the cut off point at post-treatment (see Table 33).  
Table 33 
Changes in individuals BDI-II scores from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change Cut off point ≤ 13 or 0 
Clinically 
Significant 
Patient 1 23 22 No No  
Patient 2 46 7 Yes (+) Yes * 
Patient 4 11 1 Yes (+) No  
Patient 5 11 0 Yes (+) Yes * 
Patient 6 40 17 Yes (+) No  
Patient 7 45 1 Yes (+) Yes * 
Patient 9 12 8 No No  
Patient 10 22 4 Yes (+) Yes * 
Patient 12 30 7 Yes (+) Yes * 
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 










Five out of the 11 patients who completed the RRQ-rumination subscale, showed reliable improvements in their scores and had a post-
treatment score which fell below the cut off criteria (see Table 34). Hence, these five patients were considered to have shown clinically 
significant change of improvements in their rumination, experiencing a decrease in their level of rumination after MCT.  
Table 34 
Changes in individuals RRQ-rumination subscale scores from pre-treatment to post-treatment.  
ID Pre-Treatment Post Treatment Reliable Change  Cut off point (<37.202)  Clinically Significant 
Patient 1 51 44 Yes (+) No  
Patient 2 59 35 Yes (+) Yes * 
Patient 3 53 44 Yes (+) No  
Patient 4 45 25 Yes (+) Yes * 
Patient 5 55 32 Yes (+) Yes * 
Patient 7 56 44 Yes (+) No  
Patient 8 38 36 Yes (+) Yes * 
Patient 9 55 42 Yes (+) No  
Patient 10 44 40 Yes (+) No  
Patient 11 58 42 Yes (+) No  
Patient 12 45 36 Yes (+) Yes * 
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 










Four out of nine patients who completed the PSWQ questionnaire had clinically significant changes of improvements in the PSWQ Total 
scores after undergoing MCT for their eating disorder. These individuals experienced a clinically significant changes of reduction in their worry 
levels after receiving MCT, with both a reliable improvement in their PSWQ scores and post-treatment scores that were below the cut off point 
(see Table 35).  
Table 35 
Changes in individuals PSWQ scores from pre-treatment to post-treatment.  
ID Pre-Treatment Post-Treatment Reliable Change  Cut off point (<41.144) Clinically Significant 
Patient 1 63 51 Yes (+) No  
Patient 2 78 45 Yes (+) No  
Patient 3 72 59 Yes (+) No  
Patient 4 45 27 Yes (+) Yes * 
Patient 5 62 31 Yes (+) Yes * 
Patient 7 59 51 Yes (+) No  
Patient 9 50 50 No No  
Patient 10 72 41 Yes (+) Yes * 
Patient 11 76 37 Yes (+) Yes * 
Note. * = Clinically significant change (improvement), × = Clinically significant change (deterioration) 
+ = reliable change (improvement), – = reliable change (deterioration) 
 
 





Summary of clinically significant changes after MCT intervention 
 
 It was predicted that patients receiving modified MCT for anorexia nervosa would 
experience a significant increase in weight and decrease in the severity of their eating 
disorder symptoms. Analysis revealed that after receiving MCT four out of 12 patients had an 
increase in their weight which moved their BMI scores into a healthy weight range and this 
was a clinically significant change. However, one patient also experienced a clinically 
significant deterioration in weight during the intervention. These results provided some 
support for the hypothesis that modified MCT may be useful in helping patients with 
anorexia nervosa increase weight gain.  
 Additionally, seven out of 10 patients showed a clinically significant change of a 
decrease in their EDE-Q global scores after MCT. Furthermore, analysis of the EDE-Q 
subscales found that five patients experienced a decrease in their eating disorder symptoms of 
restraint (EDE-Q restraint) and a total of eight patients showed decrease in eating concern 
(EDE-Q eating concern) after receiving MCT intervention, which were all clinically 
significant changes. Results revealed that at post-treatment four patients experienced a 
decrease in their concerns about shape (EDE-Q shape concern), which was clinically 
significant. However, no patients demonstrated any clinically significant changes in their 
concerns about weight (EDE-Q weight concern) at post-treatment.  
 In terms of GAF-ED clinician measures, since the reliable change was not calculated 
for this measure, no conclusions can be made as to whether patients made clinically 
significant changes. Analysis also revealed that based on the cut-off criteria, three out of 11 
patients who received a GAF-ED score at both pre-treatment and post-treatment, showed a 
increase in their GAF-ED scores after MCT, which meant that they had transient or no eating 
disorder symptoms present and had improved daily functioning (Mcintosh et al. 2016, APA, 
1994). As no individual analysis was conducted for the clinician measure of Global rating of 





clinical state of eating disorder, a description of the results will be summarised. Out of the 11 
patients who had received clinical ratings of the Global rating of Clinical state of Eating 
Disorder at both pre-treatment and post-treatment, results showed that nine patients had 
reduced eating disorder symptoms, with some patients experiencing more reductions in their 
symptoms than others after undergoing MCT, while two patients eating disorders symptoms 
remained unchanged and still met eating disorder criteria after MCT.  
 The results of the EDE-Q outcome measures and clinician measures used to assess if 
patients experience a reduction in their eating disorder symptoms after MCT, provided mixed 
findings. Although the EDE-Q global measure showed that the majority of patients 
experienced a decrease in their eating disorder severity, one of the EDE-Q subscales showed 
less promising results for the use of modified MCT as an intervention for anorexia nervosa 
(weight concern). Clinician measures showed that three patients showed improvements in 
their GAF-ED based on the current study’s cut-off point, while the majority of patients 
showed some improvements in their eating disorder symptom’s based on the global rating of 
clinical state of eating disorder after MCT. In all there seems to be some support for the 
hypothesis that patients with anorexia nervosa experience improvements in their eating 
disorder symptoms after receiving MCT.  
 It was also hypothesised that patients receiving MCT for their anorexia nervosa would 
experience a reduction in their maladaptive metacognitions and thought control strategies.  
 The results revealed that three out of 11 patients who completed the MCQ-30 
questionnaire had a clinically significant change of a decrease in their unhelpful 
metacognitions (MCQ-30 total) after receiving intervention. Closer analysis of the MCQ-30 
subscales found that after receiving intervention, four patients experienced a decrease in their 
positive beliefs about worry and two patients showed a decrease in their negative beliefs 
about uncontrollability and danger, which were all clinically significant changes. Analysis 





also revealed that only a single patient showed reductions in their cognitive self-
consciousness subscale scores at post-treatment, which was a clinically significant change. 
Moreover, none of the patients showed any clinically significant changes in their need to 
control thoughts and cognitive confidence subscale scores after receiving MCT.  
 None of the patients in the study showed clinically significant changes for the TCQ 
total score. Further analysis showed that none of the patients in the study showed clinically 
significant changes for any of the following outcome measures; TCQ punishment subscale 
and TCQ worry subscale. Altogether these results provided little support for the hypothesis 
that there would be a reduction in patients’ maladaptive metacognitions and thought controls 
strategies after MCT, although there were some promising findings that one third of patients 
experienced a decrease in their positive beliefs about worry after receiving MCT.  
 It was also hypothesised that patients receiving modified MCT for anorexia nervosa 
would also experience a decrease in their symptoms of ruminations, depression and worry.  
 Results showed that five out of the nine patients who completed the self-reported 
BDI-II measure had reductions in their depressive symptoms, which was a clinically 
significant change, after receiving MCT intervention. Similarly, five out of 11 patients who 
completed the self-report RRQ-Rumination questionnaire also had clinically significant 
changes of decreases in their rumination levels after intervention. Analysis of the PSWQ 
measure also revealed that four out of nine patients who completed this outcome measure, 
showed decreases in excessive worrying at post-treatment, which were clinically significant 
changes.  
 These results provide some support to the hypothesis that there is a decrease patients 
ruminations, worry and depressive symptoms after receiving modified MCT  






 Previous research studies have found that anorexia nervosa is a difficult disorder to 
treat, particularly in adults who have a history of struggling with this disorder (Ricca et al., 
2010; Fairburn, 2005). The current study explored whether MCT modified for patients with 
anorexia nervosa could be an effective intervention for this disorder. Specifically, the study 
examined whether patients diagnosed anorexia nervosa or atypical anorexia nervosa, 
receiving modified MCT would show improvements in their maladaptive metacognitions, 
thought control strategies as well as experience a decrease in their depressive symptoms, 
worry, ruminations and eating disorder symptoms. In the current study, results were analysed 
at the group level and individual level.  
 Some support was found for the hypotheses that MCT modified for anorexia nervosa 
would reduce eating disorder symptoms and increase weight gain when looking at both group 
data and individual data. Group data showed that after receiving MCT the group had reduced 
maladaptive metacognitions. However, in individual analysis there was little support of 
clinically significant changes of improvements occurring in patients’ negative metacognitive 
beliefs, need to control thoughts, cognitive confidence and cognitive self-consciousness after 
receiving intervention. However, individual analysis did show some support for the clinically 
significant change of improvement in patients positive metacognitive beliefs about worry 
after receiving MCT. The results of the current study showed that at the group level, there 
was a reduction in the use of the thought control strategy of worry after MCT, however there 
were no changes in the groups use of punishment. Moreover, there were no clinically 
significant changes observed at the individual level in patients use of worry and punishment 
as forms of thought control strategies, despite receiving MCT. More promisingly, results of 
the current study at both the group level and individual level showed some support for the 





hypothesis that patients would experience reductions in their worries, ruminations and 
depressive symptoms.  
 
Eating disorder symptoms 
 There was a mean decrease in the group eating disorder symptomology, as measured 
by the EDE-Q (global), following MCT. The group data also showed mean reductions in their 
eating concerns, restraint behaviours, shape and weight concerns. Further, the individual data 
showed that the majority of patients (seven patients) experienced clinically significant 
changes of reductions in their overall eating disorder symptoms and in particular had 
decreased concerns about eating (eight patients), following MCT. Moreover, after receiving 
intervention, five patients demonstrated less restriction over their food and four patients had 
improvements in their shape concerns, all of which were clinically significant changes. The 
current study found that patients showed no clinically significant changes of improvement in 
their concerns weight after intervention, however, there is a possible explanation for this 
finding. Women are often exposed to images of underweight models in the media, a review 
of the literature found that this can have a negative impact on women’s’ body image (Grogan, 
2016). Hence, it is unsurprising that even in a normative sample population of college 
students, women show higher levels of concerns in direct measures of weight and shape, 
compared to concerns about eating or restricting food (Quick & Byrd-Bredbenner, 2013). 
Taking this into account, alongside the fact that there were clinically significant changes of 
reduction in the majority of patients overall eating disorder symptoms (EDE-Q global) these 
findings seem to indicate some support for the hypothesis that MCT modified for anorexia 
nervosa may be effective in reducing patients eating disorder symptoms. Moreover, as 
previously stated the current study’s group data showed reductions in the groups eating 
disorder symptoms as measured by the EDE-Q which is in line with previous CBT 





intervention studies (Ricca et al., 2009). Indicating that MCT modified for anorexia nervosa 
may be comparable to CBT interventions for eating disorders. It should be noted however, 
that no statistical analyses were performed between the current study and CBT study.   
 There was also an overall increase in the patients’ mean BMI after MCT. Individual 
analysis showed that one third of patient’s achieved a healthy weight range by the end of the 
intervention, which was a clinically significant change. However, a single patient with 
atypical anorexia nervosa did experience a decrease in BMI after intervention, which resulted 
in them being underweight. Overall these findings are promising, considering that one third 
of patients in the study had atypical anorexia nervosa which meant that they were already in a 
‘healthy BMI range’ and could not have achieved the criteria set for clinically significant 
change on this measure. Furthermore, the overall mean increase in the current study’s group 
BMI after treatment, is in line with improvements in BMI seen in past intervention studies 
utilising CBT, SSCM or MANTRA as intervention for anorexia nervosa or sub-threshold 
anorexia nervosa (Ricca et al., 2009; Schimdt et al., 2015).  
 In regards to the following clinician measures used in the study to assess patients 
eating disorder symptoms, no claims about clinically significant changes can be made for the 
individual data, as reliable change was not calculated for these measures. The current study 
found that after receiving MCT, the patient group demonstrated improvements in their 
psychosocial functioning, as there was an increase in groups GAF-ED mean scores after 
MCT. However, analysis of individual data, suggested that only three patients had 
improvements in their psychological functioning. This could be due to the high cut-off point 
criteria set out in the current study, as patients needed to have either transient or no eating 
disorder symptoms with none or minor impairment in psychosocial functioning in order to be 
considered ‘improved’ in the current study. If a more lenient cut-off point threshold was used 
consisting of, “mild symptoms” (APA, 1994, p32) alongside with some psychosocial 





difficulties present although “generally functioning pretty well” (APA, 1994. p32), half of the 
patients in the group would have been considered to have ‘improved’.  
 Other findings in the present study provided support for the hypothesis that MCT 
modified for anorexia nervosa would reduce eating disorder symptoms. The current study 
showed that based on clinician ratings, the majority of patients (nine patients) demonstrated a 
decrease in eating disorder symptoms following MCT intervention. Based on those who 
received clinician ratings, three patients did not have significant eating disorder symptoms 
present by the end of the intervention; one patient displayed only a few symptoms of eating 
disorder and five patients had eating disorder symptoms present but were no longer classified 
as having a full eating disorder following intervention. Moreover, after receiving modified 
MCT, only two patients satisfied the criteria of having an eating disorder according to 
clinician ratings.    
 Overall, based on clinician and self-report measures, the findings of the current study 
seem to provide some support that modified MCT can be used to treat eating disorder 
psychopathology in patients with atypical or typical anorexia nervosa. Also there was some 
support for the hypothesis that patients would experience weight increase after MCT, as 
results showed that after MCT some patients experienced an increase in weight which placed 
them in a healthy BMI weight range.    
 
Metacognitions and thought control strategies 
 The current study found that in terms of the group data, MCT modified for anorexia 
nervosa reduced unhelpful metacognitions, which seems to provide support for the hypothesis 
that patients with anorexia nervosa would experience a decrease in maladaptive 
metacognitions following MCT. Specifically, the group showed mean decreases in their 
positive beliefs about worry, negative beliefs about uncontrollability and danger, decreases in 





their need to control thoughts and decreased cognitive self-consciousness. The results for 
cognitive confidence were statistically indeterminate, therefore, no conclusions made about 
this measure. In all, aside from the lack of conclusions that can be made about the cognitive 
confidence subscale, the rest of the findings from the group data seem to support the 
hypothesis that there is a reduction in maladaptive metacognitions in patients with anorexia 
nervosa after receiving MCT. Moreover, these current results are mostly in line with previous 
studies which show the effectiveness of MCT in reducing unhelpful metacognitions in 
individuals struggling with psychological distress (Hjemdal et al., 2017; Wells et al., 2012).  
 In terms of the current study’s individual data, a total of 11 patients completed the 
MCQ-30 outcome measure, after receiving MCT. Three out of the 11 patients showed 
clinically significant changes of improvement in their overall maladaptive metacognitions 
(MCQ-30 total), after MCT. In terms of the MCQ-30 subscales; two patients showed 
clinically significant changes of improvements in their negative beliefs about 
uncontrollability and danger and one patient showed improvements (clinically significant 
change) in their cognitive self-consciousness. Whereas no patients showed clinically 
significant changes in their cognitive confidence or their need to control thoughts. Hence, the 
current study showed little evidence of clinically significant changes across these four 
subscales. Compared to the other subscales of the MCQ, a more promising finding in the 
current study was that four patients showed improvements in their positive beliefs about 
worry, which were clinically significant changes following MCT intervention. Previous 
research also showed mixed findings in terms of clinically significant changes, where in a 
series of case studies of three individuals with binge eating disorder; two individuals had 
clinically significant changes of improvements in their negative beliefs about worry, whereas 
only one patient showed clinically significant changes of improvements in their positive 
beliefs about worry and cognitive confidence after MCT (Robertson & Strodl, 2020). 





Previous research found that no clinically significant changes were observed in the need to 
control and cognitive self-consciousness subscales in patients with binge eating disorder after 
MCT (Robertson & Strodl, 2020). Interestingly, in the Robertson & Strodl’s (2020) study 
although only one patient showed clinically significant changes of improvement in their 
positive beliefs about worry, it was found that every individual (three) in the study had 
“significant improvements” (Robertson & Strodl, 2020, p.8) in their positive beliefs whereas 
two individuals had significantly improved in their negative beliefs about worry. Therefore, 
the authors in the Robertson & Strodl (2020) study thought that in individuals with binge 
eating disorder MCT effected positive metacognitive beliefs more than negative 
metacognitive beliefs, which is in line with findings of the current study.  
Although the current study’s group data did show mean decreases in the groups 
metacognition for most of the subscales (aside from cognitive confidence) and total scores 
(MCQ-30) following MCT; individual data analysis showed that only one or two patients 
showed clinically significant changes of decrease in their cognitive self-consciousness and 
negative beliefs about uncontrollability and danger scores. Moreover, no clinically significant 
changes were found for cognitive confidence or need to control thoughts. The most promising 
finding was that four patients showed clinically significant changes of reduction in their 
positive beliefs about worry after MCT. It is possible that metacognitive changes may 
continue to occur in patients even after post-treatment outcome measures were collected. 
Based on past research, it is also possible that not all eating disorder metacognitions are 
adequately measured by the MCQ-30, as individuals with eating disorders may have other 
metacognitions, this is an area which requires more research (Robertson & Strodl, 2020; 
Vann, Strodl & Anderson, 2014).  
Overall, the results from the individual data seemed to provide only partial support for 
the hypothesis that after receiving MCT for anorexia nervosa patients’ would experience a 





reduction in their maladaptive metacognitions, with individual analysis providing some 
support for improvements in patients positive metacognitive beliefs about worry, whereas 
little support was found for the reduction of other types of maladaptive metacognitions 
(cognitive confidence, need to control thoughts, negative beliefs about uncontrollability and 
beliefs about cognitive self-consciousness) after MCT.   
 In the current study it was hypothesised that after receiving modified MCT patients 
would experience a decrease in their use of unhelpful thought control strategies. Findings 
from the group data showed that following MCT, there was a mean decrease in the groups 
use of worry as a thought control strategy. This is a promising finding as a review of the 
literature has linked thought control strategies such as worry to psychological distress (Wells 
& Fisher, 2015). However, aside from the groups decrease in worry as a thought control 
strategy, other findings in the current study provided little support for the hypothesis that 
modified MCT reduced maladaptive thought control strategies. Contrary to the prediction that 
modified MCT would result in a lower use of punishment as a mechanism to control 
thoughts, findings from group data in the current study indicate that no conclusions can be 
made as to whether any changes had occurred in the groups use of punishment following 
MCT, as the results were statistically indeterminant. The current study also found that no 
clinically significant changes in the use of worry and punishment were observed in any 
individuals after receiving MCT. Previous research examining the use of MCT for binge 
eating disorder also showed similar results, where there were no significant reductions in 
patients use of thought control strategies of worry and punishment after intervention 
(Robertson & Strodl, 2020). A possibility for the lack of clinically significant changes in 
patients maladaptive thought control strategies following intervention, may be explained by 
previous studies which indicate that for individuals diagnosed with eating disorders the 
thought control questionnaire (TCQ) may not be an entirely suitable measure (Robertson & 





Strodl, 2020; Vann et al., 2014). Interestingly though, Vann et al., 2014 did find that the 
thought control strategy of punishment was increased in clinical populations of eating 
disorders.  
 
Worrying, rumination and psychological distress 
 The current study showed some support for the hypothesis there would be a reduction 
in depressive symptoms, worry and rumination following MCT.  
There was a mean reduction in the groups depressive symptoms following MCT. 
Further, five out of the nine patients who completed the BDI-II had experienced clinically 
significant changes of decreases in their depressive symptoms. These findings provide 
support for the hypothesis that patients struggling with eating disorders may experience a 
reduction in their depressive symptoms after receiving modified MCT. This is consistent with 
recent research showing a decrease in individuals’ depressive symptoms (BDI-II) following 
MCT for binge eating disorder (Robertson & Strodl, 2020).  
 Complementary to the findings above, the current study also showed a mean decrease 
in the groups rumination and worry symptoms following MCT. This supports the current 
study’s hypothesis that there is a decrease in patients worries, ruminations and depressive 
symptoms following MCT modified for anorexia nervosa. In the current study, five patients 
showed clinically significant changes of reductions in their rumination levels after receiving 
MCT. Whereas, four patients showed clinically significant changes of decreases in their 
worrying levels following MCT. Consistent with previous research which shows that 
rumination and worries are present in eating disorders (Startup et al., 2013), the current study 
further shows that individuals with struggling with anorexia nervosa may experience a 
decrease in their ruminations and worries following MCT. These findings are also consistent 
with past studies of group data suggesting that MCT decreases ruminations and worries in 









 This exploratory study was one of the first trials to examine the use of MCT as an 
intervention for eating disorders. Previous research has combined cognitive therapy with 
metacognitive therapy to form an intervention for binge eating disorders and bulimia nervosa 
(Cooper, Todd & Wells, 2008). A recently published study also applied MCT as an 
intervention for binge eating disorder (Robertson & Strodl, 2020). The current study, 
however, is one of the first to adapt MCT as a treatment for patients with either anorexia 
nervosa or atypical anorexia nervosa. The current study shows some support of weight 
increase in some patients after receiving MCT. The present study provides some support for 
the hypothesis that that MCT modified for anorexia nervosa may be useful in reducing eating 
disorder symptoms. As indicated above, overall the patient group data showed improvements 
in self-reported eating disorder symptoms, consistent with previous CBT studies for eating 
disorders (Ricca et al., 2009). Moreover, these observed decreases in patients’ eating disorder 
symptoms are also in line with recent research showing reduced binge eating disorder 
symptoms following MCT (Robertson & Strodl, 2020). The current study is the first to show 
how adapted MCT may be a new effective form of intervention for adult patients’ struggling 
with typical or atypical anorexia nervosa. Thus, adapted MCT for anorexia nervosa may fill 
in the gap needed in the form of treatment for adults with anorexia nervosa.  
 The present study also showed a decrease in patients depressive symptoms after 
receiving modified MCT, as measured by the BDI-II, which is in consistent with the findings 
of previous research on MCT for binge eating disorders where patients showed reductions in 
depressive symptoms (Robertson & Strodl, 2020). Results of the current study also showed 





that following adapted MCT for anorexia nervosa some patients experienced reductions in 
their worry and rumination levels. These reduction in rumination and worry levels observed 
in patients in the current study from both group data and individual data analysis, provide 
support for past research theories that rumination and worry processes are present in anorexia 
nervosa (Sala et al., 2019; Startup et al., 2013).  
Moreover, in the current study, the observed decrease in patients’ ruminations and 
worrying levels following MCT adapted for anorexia nervosa, also highlights the 
transdiagnostic nature of MCT, which is consistent with previous research indicating that 
MCT can be used to treat depression and comorbid anxiety (Hjemdal et al., 2017). The 
current study extends upon previous research, as this is the first study to show that individuals 
receiving MCT modified for anorexia nervosa may not only experience a reduction in 
symptoms of depression, worry, rumination but also decreases in their eating disorder 
symptoms. As anorexia nervosa is often comorbid with anxiety and depression (APA, 2013), 
use of an MCT intervention to treat eating disorder symptoms but also comorbid disorders 
through the modification of maladaptive metacognitions was proposed by Vann et al., (2014).  
Findings from the current study seem to provide some support that MCT may be a 
practical, efficient method of treating individuals with anorexia nervosa who are also 
struggling with anxiety and depressive symptoms. Although there is some support for 
clinically significant changes of improvements in patients’ positive beliefs after MCT, it is 
not possible to conclude that these improvements in unhelpful metacognitions led to 
decreases in patients eating disorder symptoms. Further statistical analysis would need to be 
conducted to test this theory, for example past research stated the need for a mediation 
analysis to analyse processes in their own intervention study (van der Heiden, 2012).  
 
Limitations  





 The current study had several limitations. Firstly, the study was carried out as a 
sequential open trial with a small sample size. This small sample size limits the 
generalisability of the findings, there was also a lack of diversity in the sample as the 
majority of patients in the current study were NZ Europeans. Secondly, as this was an 
exploratory study, the number of therapy sessions that each patient received varied largely 
(11-42 sessions). Moreover, most of the patients in the current study had previously received 
some form of treatment for their eating disorder, as this was not controlled for in the study. 
Thirdly, the lack of a randomised controlled trial meant that there was no control group to 
compare MCT intervention with, the use of an active control group would allow researchers 
to account for the effects of meeting regularly with a therapist has on patients (Wells, et al., 
2012).  
Another limitation concerns the statistical analyses that were performed in the current 
study. Due to the exploratory nature of the current study, a more liberal approach to analysis 
was applied. Hence, the results found in the current study should be interpreted cautiously. 
The calculations used to determine statistical significance before and after intervention were 
based on the assumption that the data was normally distributed, which is unlikely to be the 
case in this current study due to its small sample size (Tryon, 2001). Moreover, as this trial 
was conducted as an exploratory study rather than a randomized controlled trial, no 
corrections were calculated for the multiple analyses performed (Tryon, 2001; Vickerstaff, 
Omar & Ambler, 2019). Another limitation was in regards to the calculations of the RCI, for 
the PSWQ measure the standard deviation and Cronbach’s alpha were derived from different 
samples. A further limitation was that there was missing data in many of the outcome 
measures used in the study, once again this was due to the exploratory uncontrolled 
sequential nature of the trial.  





For outcome measures which did not have pre-existing clinical cut-off points, the 
current study used a calculated cut-off point (2sd from pre-treatment mean) to determine 
whether patients had met one of the criteria’s needed for clinically significant change. 
However, the use of this cut-off point (2sd) may not be appropriate at times, as the cut-off 
points for certain outcome measures was below the lowest possible score for that measure 
(EDEQ-restraint subscale). It is of note that the cut-off point criteria (2sd from pre-treatment 
mean) used in the present study is in line with criteria set out by Jacobson & Truax (1991). 
Another limitation in the current study was that it was unknown whether 
dysfunctional and functional populations overlapped with each other in their distributions. 
Hence, after completion of MCT conclusions cannot be drawn about whether patients had 
fallen into a functional population group and had recovered. Even if patients achieved a cut-
off point of 2sd from pre-treatment mean at post-treatment, as it was unclear whether this 
improvement of 2sd would place them within the range of a functional population group. 
Therefore, the clinically significant change definition set by Jacobson & Truax (1991) as 
moving into a functional population was not realised in the current study; hence in the current 
study the use of the term clinically significant change did not refer to recovery into healthy 
functioning (Baer, Lambert & Nielson, 2004; Jacobson & Truax, 1991; Jacobson, Follette & 
Revenstorf, 1984; Tingey, Lambert, Burlingame & Hansen, 1996).  
 
Future research 
 In order to address some of the limitations mentioned above, future research studies 
should examine the efficacy of MCT modified for anorexia nervosa through the use of a 
randomised controlled trial (RCT) with a large sample size to allow for the generalisability of 
results. Moreover, an RCT would allow for more controlled measures to be put in place, such 
as a set number of therapy sessions for all participants and limiting entry into the trial for 





participants who have not previously received treatment for the eating disorders (Ricca et al., 
2010), in order to control for the effects of previous treatments. It would also be useful to 
compare MCT modified for anorexia nervosa to other interventions for anorexia nervosa such 
as CBT (Ricca et al., 2010), to examine which intervention may be more efficacious in the 
treatment of this particular eating disorder. Future studies could also conduct an intention to 
treat analysis in order to control for any missing data. Moreover, future studies on MCT 
modified for anorexia nervosa could also look at using more measures with pre-existing 
clinical cut-off points based on previous research (Blampied, 2017). Further research on 
MCT for anorexia nervosa could focus on recruiting patients with typical anorexia nervosa, 
as the current study included both typical and atypical anorexia nervosa. Thus, research could 
explore the use of MCT focusing solely patients with anorexia who have a low BMI to 
examine whether there are any differences in outcomes compared to the current study. 
Previous research has suggested that metacognitions in eating disorders are transdiagnostic, 
and interventions should aim to change these unhelpful metacognitions (Vann et al., 2014), 
thus, further research is needed to see if MCT modified for anorexia nervosa would also be 
an effective intervention for other types of eating disorders.  
 
Conclusion 
Anorexia nervosa is known to be a difficult psychological disorder to treat in adults 
(Fairburn, 2005). The current exploratory study examined the effectiveness of a new form of 
treatment, MCT modified for anorexia nervosa, for those struggling with this particular eating 
disorder. There was some evidence in the current study patients with anorexia nervosa 
experienced a decrease in eating disorder symptoms and some experienced an increase in 
BMI after MCT. Findings also showed that although group data indicated a mean decrease in 
patients maladaptive metacognitions across several subscales after MCT and individual 





analysis provided some support for clinically significant changes of reductions in positive 
beliefs about worry after receiving MCT; there was a little support for clinically significant 
changes of improvements observed in most of the patients unhelpful metacognitions such as 
patients need to control thoughts, their cognitive confidence, negative metacognitive beliefs 
about worry and cognitive self-consciousness following MCT. Hence only partial support 
was found for the hypothesis that those receiving MCT adapted for anorexia nervosa 
(atypical and typical) would experience a reduction in their maladaptive metacognitions. The 
current study also found a mean decrease in the groups use of worry as a thought control 
strategy after intervention, however as there was a lack of clinically significant findings for 
this TCQ worry measure, and punishment there is little support for the hypothesis that MCT 
is a useful treatment for changing patients thought control strategies. Based on the findings 
from group and individual data, the current study showed that following modified MCT for 
anorexia nervosa some patients showed reductions in depressive symptoms, worrying and 
rumination levels. Although the current exploratory study examining MCT for anorexia 
nervosa has shown some promising findings in the use of this treatment for patients 
struggling with atypical and typical anorexia nervosa; a more robust randomised controlled 
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Participant Information Sheet 
 
You are invited to take part in a study evaluating Metacognitive Therapy for Anorexia 
Nervosa. Whether or not you take part is your choice. If you don’t want to take part, you 
don’t have to give a reason, and it won’t affect the care you receive in any way. If you do 
want to take part now, but change your mind later, you can pull out of the study at any 
time.   
 
This Participant Information Sheet will help you decide if you’d like to take part. It sets out 
why we are doing the study, what your participation would involve, what the benefits and 
risks to you might be, and what would happen after the study ends. We will go through this 
information with you and answer any questions you may have. We expect this will take 
about 10 minutes. You may also want to talk about the study with other people, such as 
family, whānau, friends, or healthcare providers. Feel free to do this. 
 
If you agree to take part in this study, you will be asked to sign the Consent Form on the last 
page of this document and return it to your Clinical Psychologist. You will be given a copy of 
both the Participant Information Sheet and the Consent Form to keep.  This document is 5 
pages long, including the Consent Form. Please make sure you have all of the pages. 
 
Study title: Metacognitive Therapy for Anorexia Nervosa; an open trial in the SIEDS 
Locality: Princess Margaret Hospital 







Dr Janet Carter 
Ms Rachel Lawson 
Contact phone 
number: 
03 366 7001  
03 3377707 
 





1. Why are we doing the study? 
The main purpose of this study is to evaluate the effectiveness and feasibility of 
Metacognitive Therapy (MCT) for outpatients at the South Island Eating Disorder Service 
with Anorexia Nervosa. Metacognitive Therapy is a psychological treatment that focuses on 
changing the way people respond to their thoughts. Metacognitions, or your thinking about 
your thoughts, determines whether those thoughts are dismissed or whether they are 
dwelled upon (worry and rumination).  Worry and rumination can lead to prolonged and 
deeper distress and maintain unhelpful eating behaviours. Studies that have examined the 
effectiveness of MCT have shown it to be an effective treatment for several types of mental 
health difficulties such as anxiety and depression. This study is the first to evaluate whether 
MCT is an effective and acceptable treatment for Anorexia Nervosa.  
2. What will your participation involve? 
Your participation in this study will involve completing 10-20 sessions of Metacognitive 
Therapy.  MCT sessions involve learning new skills to better manage the unhelpful thinking 
that occurs in Anorexia nervosa.  Your therapist will assist you to understand and apply 
these skills to your particular problems.  MCT is offered as a standard treatment at the 
South Island Eating Disorder Service, so even if you do not wish to participate in this study 
you may be eligible to receive this treatment.  If you have been prescribed medication then 
you will continue to take this. 
All referrals to the SIEDS are asked to complete questionnaires as part of the normal 
assessment process. If you choose to participate in this study however you will be asked to 
complete a number of additional questionnaires at the beginning, middle, end, and 3 
months after the end of treatment. The questionnaires will be given to you by your Clinical 
Psychologist and will ask about eating disorder symptoms, self-esteem, worry, anxiety and 
body image. The questionnaires will take approximately 60-90 minutes to fill out. If you 
agree to participate in this study you will be asked if you give consent for the information 
from your assessment questionnaires to be given to the research team so it can be included 
with the study questionnaire information.  The research team is Rachel Lawson (Clinical 
Head and Registered Clinical Psychologist at SIEDS) and Janet Carter (Associate Professor at 
the University of Canterbury and Registered Clinical Psychologist). 
3. What are the possible benefits and risks to you of participating? 






It is possible that some of the questions within the questionnaires may bring up sensitive 
issues and cause some distress. Remember though that you are free to withdraw at any 
time during this study. However, if you feel any distress during the completion of the 
questionnaires please let your clinical psychologist know. You may also find filling out the 
questionnaires tiring. It is OK to take breaks when filling out the questionnaires. 
If your clinician becomes aware of any factors (i.e. your health declines to a level that means 
it is no longer appropriate for you to receive MCT) that means you can no longer participate 
in the study, you will informed as soon as possible. 
4. What are the rights of participants in the study? 
 
As a voluntary participant in this study, you are free to decline to participate, or to withdraw 
from the study at any time and have the information collected from you destroyed.  
You have the right to access information that is collected from you in the study and you can 
choose to receive a report of this study’s results at the end of the study. Your privacy will be 
respected as the information that you provide will be coded and stored separately from the 
Consent Form with your name on it. 
Section 32 of the Accident Compensation Act 2001 sets out the limited circumstances in 
which there will be ACC cover for ‘personal’ (physical) injury suffered as a result of 
treatment provided as part of this intervention study.  However given this study is 
examining a psychological intervention there is very low risk of physical injury.   
5. What will happen after the study ends, or if you pull out? 
 
You will be able to continue to receive MCT if you withdraw from the study.  All information 
that is collected from you will be coded and stored in a locked place as well as a password 
protected computer database, until it is destroyed after 10 years (all paperwork will be 
shredded and all electronic information deleted). This is the responsibility of the Central 
Researcher (Dr Janet Carter). Before it is destroyed, members of the research team will have 
access to this coded information. Your coded information may contribute to an analysis that 
could be published in a scientific journal. If you choose to receive a report of this study’s 
results at the end of the study, the expected timeframe for receiving this report is six 
months after the end, which will be December 2015. 
 





Where can you go for more information about the study, or to raise concerns or 
complaints? 
If you have any questions, concerns or complaints about the study at any stage, please feel 
free to contact any member of the research team: 
 
Janet Carter     Rachel Lawson 
University of Canterbury   South Island Eating Disorder Service 
Phone:  03 3642987 ext. 8090   Phone: 03 3377707 
Email: janet.carter@canterbury.ac.nz  Email: Rachel.Lawson@cdhb.health.nz 
 
Alternatively, if you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
Phone:   0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@hdc.org.nz 
 
You can also contact the ethics committee that reviewed and approved this study on: 
Phone:  0800 4 ETHICS 
Email:  hdecs@moh.govt.nz 
 
If you wish to contact Pukenga Atawhai (Maori Mental Health Service), please contact the 
South Island Eating Disorders Service at: 



























Participant Consent Form 
Declaration by participant: 
• I have read and I understand the Participant Information Sheet. I have had the 
opportunity to ask questions and I am satisfied with the answers I have received. 
• I freely agree to participate in this study.   
• I have been given a copy of the Participant Information Sheet and Consent Form to 
keep. 





• I have been given the opportunity to meet with the Pukenga Atawhai 
• I consent to the research team been given a copy of my assessment questionnaires 
completed at the South Island Eating Disorder Service  
Participant’s name: 
Signature: Date: 
Email or Postal Address: 
 
Study title: Metacognitive Therapy for Anorexia Nervosa; an open trial in the SIEDS 
Locality: Princess Margaret Hospital 


















Researcher’s signature:                                                       Date: 
  
Please indicate whether you would like to receive a report of this 
study’s results: Yes / No 
  








Health and Disability Ethics 
Committees 
Min
istry of Health C/- 
MEDSAFE, Level 6, Deloitte 
House 
10 Brandon Street 














Private Bag 4800 
Christchurch 8140 
 
Dear Associate Professor Carter 
 
 
Re: Ethics ref: 14/NTB/19 
 Study title: Metacognitive Therapy for Anorexia Nervosa: An open trial in the 
South Island Eating Disorder Service 
 
 
I am pleased to advise that this application has been approved by the Northern B 
Health and Disability Ethics Committee. This decision was made through the 
HDEC-Full Review pathway. 
 
The main issues considered by the HDEC in giving approval were as follows. 
 
• The Committee thanked Associate Professor Janet Carter for making the 
time to speak to the Committee. 
• The Committee noted the adjustments to the protocol in response 
to the declined application which has made it a safer study for 
participants. 
• The Committee noted that the application and participant information 
were clear and easy to understand and thanked Associate Professor 
Janet Carter for addressing the questions raised in the decline letter. 
• The Committee asked for the timing of recruitment. Associate Professor 
Janet Carter explained that when a referral comes to the South Island 
Eating Disorder Service (SIEDS) patients fill in questionnaires and are 
allocated a clinician. These assessments are taken to a clinical team 





meeting where a plan is agreed on for a patient, for example, patients may 
be allocated a therapist, physiotherapist, psychiatrist or dietician. Patients 
will then agree to this plan. 
• Associate Professor Carter noted that metacognitive therapy has been done 
in SIEDS for some time with individuals and groups and that she wants to 
collect data on its effectiveness. 
• The Committee noted that the researcher wants patients to be on stable 
medications and noted that dosages might be changed by psychiatrists. 
Associate Professor Carter explained that while they would prefer 
patients to be on stable medication, this won’t necessarily happen as 
some patients will have their medication changed. Any changes to 
medications will be noted. 
• Associate Professor Carter confirmed that the planned commencement 
date of February 2015 was a typo. 
• The Committee asked for clarification on the number of weekly 
sessions. Associate Professor Carter confirmed that the aim will be 
weekly for at least the first four weeks, with a total of 10 to 20 sessions. 
• The Committee asked for the source of the funding of the study as this was 
not clear in the application (R.5.1). Associate Professor Carter confirmed 
that there was no external funding and that the study would be funded 
within the SIEDS’s existing budget. She explained that she has an RA who 
helped with putting an application together and will assist with some of the 
data input and administration. 
• The Committee queried the response to F.1.1 and F.1.2 on how the 
study would contribute to reducing inequalities between different 
populations. Associate Professor Carter was unsure if there would be 
any Māori patients and if the metacognitive therapy would be 
particularly beneficial to Māori or Pacific people but that it was hoped 
that it would be. 
• Associate Professor Carter confirmed that the New Zealand census 
question would be used for collecting ethnicity data. 
• The Committee requested the following changes to the participant 
information sheet and consent form: 
o Please tell participants to take medication that is prescribed to them. 
o Please tell participants that they will continue to receive 
metacognitive therapy if they choose to withdraw from the 
study. 
o In the consent form, please tell participants that the study 
team will be telling their GPs that they are taking part in this 
study. 
 
Conditions of HDEC approval 
 
HDEC approval for this study is subject to the following conditions being met 
prior to the commencement of the study in New Zealand. It is your 
responsibility, and that of the study’s sponsor, to ensure that these conditions 
are met. No further review by the Northern B Health and Disability Ethics 




1. Before the study commences at any locality in New Zealand, all 
relevant regulatory approvals must be obtained. 
 





2. Before the study commences at any locality in New Zealand, it must be 
registered in a WHO-approved clinical trials registry (such as the Australia New 
Zealand Clinical Trials Registry, www.anzctr.org.au). 
 
3. Before the study commences at a given locality in New Zealand, it must be 
authorised by that locality in Online Forms. Locality authorisation confirms 
that the locality is suitable for the safe and effective conduct of the study, 




• Please amend the PIS and consent form, taking into account the 
suggestions made by the Committee (Ethical Guidelines for Intervention 
Studies, para 6.22). 
 
Non-Standard conditions must be completed before commencing your study. 
Please email non-standard conditions to HDECS@moh.govt.nz. Do not 
submit non-standard conditions as a Post Approval form. 
 
After HDEC review 
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements relating 
to amendments and other post-approval processes. 
 
Your next progress report is due by 10 
March 2015. Participant access to ACC 
The Northern B Health and Disability Ethics Committee is satisfied that your 
study is not a clinical trial that is to be conducted principally for the benefit of 
the manufacturer or distributor of the medicine or item being trialled. 
Participants injured as a result of treatment received as part of your study may 
therefore be eligible for publicly-funded compensation through the Accident 
Compensation Corporation (ACC). 
 
Please don’t hesitate to contact the HDEC secretariat for further information. 
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Document Version Date  
Declined letter for previous application in respect of the same (or 
substantially similar) study 
1 17 September 2013  
CV for CI 1 15 August 2013  
PIS/CF 2 04 February 2014  
Protocol 1 15 August 2013  
Survey/questionnaire 1 15 August 2013  
Survey/questionnaire 1 15 August 2013  
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Survey/questionnaire 1 15 August 2013  
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Statement of compliance and list of members 
 
Statement of compliance 
 
The Northern B Health and Disability Ethics Committee: 
 
¾ is constituted in accordance with its Terms of Reference 
¾ operates in accordance with the Standard Operating Procedures for Health and 
Disability Ethics Committees, and with the principles of international good clinical 
practice (GCP) 
¾ is approved by the Health Research Council of New Zealand’s Ethics Committee for the 
purposes of section 25(1)(c) of the Health Research Council Act 1990 
¾ is registered (number 00008715) with the US Department of Health and Human 
Services’ Office for Human Research Protection (OHRP). 
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